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SUMMARY
Multistrain HIV-1 Elimination:
A CRISPR-Cas9 and Theranostics-based Approach
Jonathan Herskovitz, Ph.D.
University of Nebraska Medical Center, 2020
Mentor: Howard E. Gendelman, M.D.

A critical barrier to achieving a functional cure for infection by human immunodeficiency
virus type one (HIV-1) rests in the presence of latent proviral DNA integrated in the nuclei
of host CD4+ T cells and mononuclear phagocytes. Accordingly, HIV-1-infected patients
must adhere to lifelong regimens of antiretroviral therapy (ART) to prevent viral rebound,
CD4+ T cell decline, and progression to acquired immunodeficiency syndrome (AIDS).
Gene editing using clustered regularly interspersed short palindromic repeat (CRISPR)Cas9 technology stands as one means to inactivate integrated proviral DNA. We devised a
mosaic gRNA CRISPR-Cas9 system- TatDE- that targets viral transcriptional regulator
genes tat / rev, while also accounting for clinical HIV-1 sequence diversity. TatDE
effectively reduced viral replication in all 7 HIV-1 strains tested by an average of 82%, and
attenuated latency reversal in HIV-1-infected ACH2 T cells by 94%. In establishing the
TatDE system, we identify a positive association between CRISPR target conservation and
antiviral efficacy. Moreover, TatDE’s simultaneous cleavage of 5 HIV-1 exons (tat1-2 /
rev1-2 / and gp41) suggest that exonic disruption may be a guiding principal in designing
CRISPR for HIV-1 elimination. Limitations to utilizing an alternate vector, recombinant
adeno-associated virus 9 (rAAV9), for HIV-1 removal are experimentally addressed.
Preliminary data exploring the design of virus-like particles and nanoparticles for CRISPR-
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Cas9 delivery are presented. To guide the development of curative nanoparticles for HIV1 infection, europium sulfide (EuS) theranostic nanoprobes were devised. EuS aided in the
identification of dynamin-mediated endocytosis as a mechanism for particle uptake in
CD4+ T cells and macrophages. Additionally, EuS facilitated the non-invasive
characterization of nanoformulation biodistribution using magnetic resonance imaging
(MRI) and single photon emission computed tomography (SPECT-CT). Thus, advances in
the arenas of molecular biology, theranostics, and material science coalesce in providing a
pathway towards HIV-1 elimination.
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CHAPTER 1
Introduction
Defining Disease and a Pathway Toward Cure

1.1 Significance of HIV-1 and the Need for Curei
With an estimated 38 million people living with human immunodeficiency virus type
I (HIV-1) and 1.7 million new infections in 2019, HIV-1 remains a global health concern.
To curb the spread of HIV-1, the World Health Organization has organized the 90-90-90
initiative to improve HIV-1 testing and continued treatment access to 90% of infected
individuals1. A barrier to the plan’s success is the strict lifelong adherence to combination
antiretroviral therapeutic (cART) regimens that patients must adhere to. Interruption of
cART can result in viral rebound within weeks2,3 and progress to acquired
immunodeficiency syndrome (AIDS) over a period of 7-15 years4. A functional cure for
HIV-1 that can lift the necessity for cART is actively sought5.
HIV distinguishes itself as a unique lentivirus within the family Retroviridae.
Retroviruses carry positive-sense single stranded RNA in roughly 120 nanometer
envelopes. They reverse-transcribe genomic RNA using viral enzymes into DNA, prior to
returning to the central dogma in which DNA transcribes RNA that in turn translates
protein. Common features of the lentiviruses include their utilization of monocyte /
macrophage lineages as cellular hosts, extended incubation periods prior to terminal

i

Adapted with permission from “HIV and the Macrophage: From Cell Reservoirs to Drug
Delivery to Viral Eradication”, Herskovitz & Gendelman, J. Neuroimmune Pharmacol.
(2019)
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disease, viral persistence in face of vigorous immunity, and ability to cause progressive
health decline in the absence of treatment6. HIV’s approximately 10 kilobase (kb) genome
encodes three canonical structures shared among all lentiviruses. Gag gives rise to core
structural elements: matrix, capsid, and nucleocapsid. Enzymes necessary for survival that
include reverse transcriptase, RNase-H, and integrase result from HIV’s pol sequence.
Finally, the env gene produces surface and transmembrane proteins utilized in recognition
and entry of virus into target cells. Six accessory proteins are transcribed from open reading
frames in the HIV genome. Vpr transports pre-integrated viral DNA into the nuclei of nondividing cells. Tat (trans-activator of transcription) enhances transcriptional elongation by
recognizing stem loops known as the Tat activation region (TAR). Rev, the only accessory
protein common to all lentiviruses, carries full-length and singly spliced HIV transcripts
from the nucleus to cytoplasm. Vif increases viral infectivity and assembly. Vpu, found
only in HIV-1, and Nef decrease CD4 expression leading to enhanced release of virus.

1.1.a HIV Life Cycle
HIV gene products facilitate eight major steps in the viral lifecycle of HIV6. The
process begins with (1) attachment of envelope glycoproteins that bind cellular primary
CD4 receptors and chemokine co-receptors CCR5 or CXCR4. Next, (2) entry ensues as
HIV transmembrane protein fuses with plasma membrane, followed by pore formation and
deposition of viral core into the host cell. Uncoated viral products potentiate (3) reverse
transcription and (4) integration of proviral DNA into the host’s chromosome with a usual
frequency of 10 copies per cell. Gene expression and post-transcriptional regulation
represent the fifth (5) stage of productive infection by HIV. Full-length or singly spliced
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RNA transcripts encode gag and pol, or env proteins, respectively. Proteases cleave Gag
and Env polyproteins, which are each subsequently fatty acylated or N-glycosylated. Small
multiply spliced RNAs comprise a minority of HIV transcripts that translate into the
aforementioned accessory proteins. Complexes of envelope glycoproteins and gagpolyproteins classically thought to form at the plasma membrane or late endosomes signal
(6) assembly of proviral elements. This also triggers the virus to regulate cellular endocytic
trafficking of proteins and cytoskeletal rearrangement, which culminate in (7) budding
from the host-cell. Finally, (8) maturation progresses as gag polyprotein is cleaved during
the penultimate step and thereafter, new progeny virions are spawned.
Four phases characterize the disease course of HIV in the absence of antiretroviral
treatment7. During the first month post-infection, known as the window period, HIV RNA
accumulates as CD4+ T lymphocyte counts begin to decline. Acute infection, marked by
flu-like symptoms, presents in the following month. During this phase, viral RNA peaks
while CD4+ counts reach a relative nadir, permitting for viral dissemination and seeding of
lymphoid organs. HIV next enters latency as cellular and humoral immune responses fight
back against viremia. Symptoms subside from the third month to approximately five years
after infection in concert with HIV RNA decline (<104 copies / mL) and CD4+ T
lymphocyte rebound. Resting memory CD4+ T cells8 and monocytes9 both harbor
integrated HIV without demonstrating viral replication. Viral reactivation occurs once
monocytes differentiate into macrophages upon reaching tissues10. Final crisis results 7-15
years post-infection with HIV-1, but is vastly delayed in the case of HIV-211. Patients
become progressively immunocompromised as viral replication depresses CD4+ counts
below 400/mm3. Acquired Immunodeficiency Syndrome (AIDS) is diagnosed when
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exceedingly rare infections manifest that fewer than 200 CD4+ T lymphocytes are left
circulating per milliliter blood.

1.1.b Cell Tropism
HIV readily infects CD4+ T cells and mononuclear phagocytes (MP; monocytes,
macrophages, and dendritic cells) due to the presence of necessary receptors on their
plasma membranes. HIV envelope glycoprotein 120 (gp120) initiates attachment to host
cell CD4, prompting a conformational shift that exposes sites on gp120 for secondary
connections to chemokine receptors, CCR5 or CXCR4. Subsequent binding of cell
membranes to viral gp41 allows HIV fusion and entry. Viral strains (R5) that selectively
recognize CCR5 can replicate in macrophages (M-Tropic) or CD4+ T lymphocytes12,13,
while others (X4) that principally utilize the CXCR4 co-receptor produce higher number
of viral progeny in CD4+ T cells and T-cell lines14. Monocytes display basal amounts of all
three HIV receptors in their resting state, but growth factors alter this expression upon
differentiation to macrophages or dendritic cells (DC). Monocyte colony stimulating factor
(M-CSF) induces macrophages to upregulate CCR5 by 10-fold whereas GM-CSF
markedly decreases CXCR4 among dendritic cells15. M-tropic strains predominate in both
early6 and late16 disease states. This correlates with times of high transmissibility and
terminal CD4+ T lymphocyte depletion, respectively. In contrast, X4-viruses appear most
frequently in patients transitioning between early and intermediate phases6. CCR5mediated entry of HIV into macrophages indicates the underlying potential for disease state
to progress.
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The beta-chemokine receptor, CCR5, has long been recognized as important to
HIV-1 infection. Mutations in CCR5 may confer HIV resistance in human hosts by halting
entry of M-tropic HIV-1 clades17,18 and delay AIDS progression in heterozygotes19,20. A G
protein-coupled receptor, CCR5 serves as a docking site for CC motif chemokine ligands
MIP-1α (CCL3), MIP-1β (CCL4), and RANTES 21. High concentrations of these proteins
correlated with low levels of viremia in patients, and were essential to natural killer (NK)
cell cytotoxicity of infected CD4+ T lymphocytes22. Furthermore, HIV-patients with low
or undetectable plasma levels of virus, known as elite controllers, were found to maintain
elevated blood concentrations MIP-1α, MIP-1β, and RANTES23. Thus, physiological
blockade of CCR5 presents one adaptive means of interrupting HIV infection in
macrophages.
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1.2 HIV-1 Latency: An Obstacle to Viral Elimination
The term “HIV-1 latency” was used initially in reference to the asymptomatic
period between acute infection and the development of AIDS24. In the absence of cART,
HIV-1 replicates freely during the asymptomatic period while sparing CD4+ T cell decline.
Antiretroviral drugs have been developed to interfere with early phase (entry, fusion,
reverse transcription, integration) and post-translational (proteolytic cleavage, assembly
and maturation) stages of HIV-1 replication25. Administration of cART halts HIV-1
proliferation, CD4+ T cell death, and risk of transmission26. Standard of care highly active
antiretroviral therapy, consisting of three or more drugs from at least two antiretroviral
classes, check this viral growth. Decades of drug treatment nonetheless fail to deplete the
pool of infected CD4+ T cells27. As the half-lives of CD4+ T lymphocytes are roughly 1
day, understanding how the threat of viral rebound outlasts the lifespans of the cells they
infect requires clarification.
Latency reversal upon discontinuation of cART stems from two cellular pools,
cumulatively referred to as viral reservoirs: CD4+ memory T cells and mononuclear
phagocytes. Evidence for CD4+ memory T cells serving as a major latency pool arises
from the finding that HIV-1 does not efficiently infect resting CD4+ T cells28, but instead
requires immune activation. Accordingly, the majority of CD4+ T cells that encounter
cross-presented HIV-1 antigen face viral cytopathic decline, but a minority return to G0
and serve as long-lived CD4+ memory T lymphocytes29. Viral outgrowth assays of blood
and lymph nodes from HIV-positive patients reveal that one per million resting CD4+ T
cells harbor replication competent HIV-130. The monocyte / macrophage lineage represents
a second potential source of latent HIV-1. Monocytes have been characterized as infectible
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by HIV-131. Although monocytes circulate in blood for approximately one day24, their
ability to differentiate into macrophages in tissues serves as a means of trafficking HIV-1
to non-lymphoid organs. Such has been characterized in the central nervous system
(CNS)32 where infected microglia contribute to viral persistence and HIV associated
dementia33,34. Mononuclear phagocytes are believed to serve as a major source of HIV-1
during terminal disease when CD4+ T lymphocytes are depleted, as has been observed in
non-human primate studies35. Thus, curative efforts must consider removal of proviral
DNA from both cellular sources whose long-lived accumulation in lymphoid and CNS
tissues are difficult to target therapeutically.
Three molecular mechanisms are thought to regulate HIV-1 latency: epigenetics,
transcriptional interference, and RNA export. Unlike herpes simplex viruses (HSV), which
encode specific latency associated transcripts36 and microRNAs37 to silence infection in
neurons, HIV-1 latency is an artifact of cART treatment. Support for the epigenetic
approach arose with the findings that HIV-1 proviral DNA has been identified in
heterochromatin regions within latently infected JLat T cell lines38 and that nuc-1
nucleosomes are consistently associated with the virus’ 5’ LTR region39. Furthermore,
cytosine methylation that represses gene expression occurs on two CpG island motifs that
flank the HIV-1 transcription start site40. However, the finding that HIV-1 preferentially
integrates within expressed host genes41 indicates that chromatin conformation cannot
solely govern the reduction of viral transcripts. Transcriptional interference, which
operates even in euchromatin DNA regions, serves as a second mechanism to block
expression of viral genes. When HIV-1 proviral DNA integrates in opposite polarity to that
of host genes, transcription of host genes also synthesize interfering RNAs with
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complementarity to viral transcripts and further prompts collision with RNA Pol II actively
transcribing viral mRNA42. Yet, proviral DNA displays a tendency to integrate in the same
orientation as human exons43. In this scenario, expression of upstream host genes is thought
to displace viral transcription factors NFκb, NFAT, and SP-1 from their binding to the viral
promoter, 5’ LTR. Control of transcriptional elongation via HIV-1 Tat stands as a final
means to regulate viral latency44. In latent conditions, viral transcription driven by NFκb,
NFAT, and AP-1 ceases prematurely at ~60 base pairs due to RNA polymerase II blockade
by negative elongation factor (NELF)24. HIV-1 tat enables full-length mRNA transcription
by forming a positive transcription elongation complex (P-TEFb; includes CDK9 and
cyclin T1) that binds the transactivation-responsive element (TAR), an RNA stem-loop
structure located at the 5’ end of all viral transcripts45. Tat-TAR operate together to displace
inhibitors from RNA polymerase II and NELF from proviral DNA46. Thus, modulation in
the cytoplasmic and nuclear distribution transcription factors in the context of cART
withdrawal or immune stimulation plays a vital role in latency reversal. Gene editing for
HIV-1 cure must therefore account for the contributions of epigenetics, interfering RNAs,
and transcription factors in designing therapies that can identify targets in heterochromatin
states without reseeding newly synthesized proviral DNA.
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1.3 Utilizing CRISPR-Cas9 for HIV-1 Therapyii
A prime success of CRISPR-Cas technology has been its utility in deactivating the
human immunodeficiency virus (HIV). Befittingly, clustered regularly interspersed
palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas), first identified as
microbial defenses against viruses, offer a means of eliminating HIV, the causative agent
of acquired immunodeficiency syndrome (AIDS) from humans. The major hurdle to this
feat rests in the need to remove latent proviral DNA integrated from within host CD4+ T
cells and mononuclear phagocytes in all body tissues47. In the absence of combination
antiretroviral therapy, unchecked viral replication in these immunocytes contributes to
CD4 cell decline and leaves individuals susceptible to opportunistic infections. Unlike
conventional anticancer and antimicrobial therapeutics, obtaining a functional cure for
HIV/AIDS must spare the same cells targeted by the pathogen. CRISPR guide RNAs
(gRNA) direct Cas endonuclease “molecular scissors” to specifically targeted ~18-25
nucleotide sites. CRISPR-Cas can thus cleave proviral DNA while leaving the host genome
intact. Herein, we review how CRISPR-Cas has been stepwise employed to offer proof-ofconcept for HIV elimination. Different strategies apply gRNA to either directly target the
HIV genome or host-encoded proteins that contribute to viral persistence. Assessment of
off-target cleavage and toxicities remain central to the evaluation of CRISPR-based gene
therapies. Other concerns addressed in the literature include the induction of resistant HIV
strains as well as identification of suitable modes for CRISPR delivery. These include ex
vivo DNA transfection, viral based transduction, and various encapsulations of gRNA or

ii

Adapted with permission from “Pathways Toward a Functional HIV-1 Cure: Balancing
Promise and Perils for CRISPR Therapy”, Herskovitz et al., Book Chapter in HIV
Reservoirs: Modeling, Quantification, and Approaches to a Cure Springer Nature (2020)
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gRNA/Cas9 ribonucleoproteins (RNPs). A more limited number of studies have sought to
fully remove all traces of HIV at both the cellular and organismal levels.

1.3.a Evolving Towards a Therapy
The CRISPR system utilized by unicellular organisms to defend against phage for
eons has seen its most rapid evolvement in the past decade, aided in part by molecular
biologists. Bacteria and archaea developed means of specifically recognizing foreign viral
genetic material (DNA or RNA) by integrating fragmented sequences, termed
“protospacers”, in CRISPR gene arrays. Expression of these gene arrays gives rise to
several catalytic cascade enzymes and three main defense elements: Cas endonuclease,
CRISPR RNA (crRNA), and trans-activating CRISPR RNA (tracrRNA; present in Type I
CRISPR systems). Because of nucleotide base pair (bp) complementarity, Cas
endonucleases are escorted to protospacer-targeted sequences by tracrRNA:crRNA
complexes. However, activation of the Cas catalytic cutting domain requires the presence
of a 2-6 base pair protospacer adjacent motif (PAM) sequence immediately downstream of
target sequences. PAM sequences, RNA or DNA substrate preferences, cutting patterns,
and proximities of nucleotide cuts relative to PAM are properties unique to each Cas
protein. In 2012, tracrRNA:crRNA encoding elements were genetically engineered into
“single guide RNAs” that enabled users to program Streptococcus pyogenes Cas9 (spCas9)
for cleavage of target DNA48. This advancement quickly gave rise to CRISPR-mediated
genome editing, whose ease of use and precision rapidly displaced older transcription
activator-like effector nucleases (TALEN) and zinc-finger nuclease (ZFN) methodologies.
The 2020 Nobel Prize in Chemistry recognizes Jennifer Doudna and Emmanuelle
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Charpentier, who first demonstrated selective employment CRISPR-Cas via custom
gRNA, for their monumental scientific contribution49.

1.3.b Inactivating the HIV Genome
Direct inactivation of the HIV genome with CRISPR-Cas9 represents one of the
most appealing approaches to achieving a functional cure (Figure 1.1A). Identifying the
most efficacious target sites, determining ideal multiplex gRNA combinations, and
ensuring broad coverage against multiple strains remain key points of focus in the field.
Pan-genome gRNA-mediated HIV knockdown screens elucidate the utility of
multiplexed, LTR-directed CRISPR therapies. The 9,719 base pair genome of HIV encodes
two long terminal repeat (LTR) regions that flank 9 viral genes that include 3 structural
genes (gag, pol, env), 2 regulatory genes (tat, rev), and 4 accessory genes (vif, vpr, vpu,
nef). Online tools have revealed hundreds of candidate sites along the HIV genome for
spCas9 gRNAs50. Consistently, regions within the U3 and R subregions of LTR have
shown the greatest repression of HIV in transfection experiments51-54. These have extended
to protection of T cells and macrophages from HIV challenge51 as well as reduced HIV
latency reversal after stimulation52. Similar findings were also reported when
Staphylococcus aureus Cas9 (saCas9)53 and Cas12a54 were utilized. Three rationales likely
contribute to the efficacies of LTR-directed CRISPR therapies. Firstly, LTR serves as the
HIV promoter and as such, its impediment dysregulates replication from remaining viral
genes28. Secondly, the dual presence of LTR enables two sites for CRISPR endonuclease
activity. The latter facilitates the dropout of nearly all 9.7 kilobases of intervening proviral
DNA55,56. Finally, because Cas9 is effective in both the cytoplasm as well as the nucleus,
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LTR-targeting gRNAs can degrade proviral DNA prior to nuclear integration thereby
reducing viral setpoints in cellular populations57. It is thus apparent that the noncoding
nature of HIV’s long terminal repeats provides a target for CRISPR-based gene therapy
that conventional drugs would fail to affect.
CRISPR gRNAs have also been effectively deployed against HIV-encoded exons
gag, pol, and tat/rev. Proviral genome-wide CRISPR screens demonstrated approximately
3-4 fold lower reduction in HIV when single gag- or pol-directed versus LTR-directed
gRNAs for spCas9 were utilized51,52. Cas13a, which cuts target RNA, contrastingly
exhibits the highest antiretroviral effect against HIV with gag-directed crRNA (gRNA
equivalent as Cas13a lacks tracrRNA)58. A robust Cas9 dual gRNA excision system
targeting LTR – U3 and gag was recently developed. Although the most profound
reduction in HIV signal was observed when LTR and pol were targeted together, the group
identified p17 (MA)-directed GagD as a suitable therapy for future works59. Two gRNAs,
GagD and LTR-1 which are compatible with the more genetically compact saCas9,
successfully reduced 77% of gag RNA in transgenic rat blood when transduced by
recombinant adeno-associated virus (rAAV9)2. Whether the improved efficacy of dual
gRNA therapy results from excision or higher rates of inactivating mutations remains a
contested topic60. An alternative to destroying LTR-based promoter activity lies in
abolishing the main driver of HIV expression, transactivator of transcription (tat). This
protein, encoded by two alternatively spliced exons overlapping with rev (exporter of viral
RNA from the nucleus), binds to the R domain of LTR and promotes viral RNA
transcription. Although modest HIV knockdown was observed with gRNA against the first
exon of tat61, more than 90% reduction resulted using gRNA targeting the second tat/rev
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exon62 or both exons63. A limitation to utilizing gRNAs that are complementary to HIV
exons is the strict necessity for full base pair matching as single mismatches not only
compromise CRISPR cutting64 but may give rise to viral escape mutants as well (Figure
1.1B).
Despite robust demonstrations that CRISPR-Cas9 durably represses HIV
replication in controlled cell-based experiments, evaluating how well these gRNAs might
work against different HIV subtypes or intrapersonal quasipecies remains a critical issue
in moving this technology from the laboratory bench to the patient. A 2017 in silico study
revealed that although 89% of published gRNA lie within 2 edit distances from consensus
sequences, only 4 of the 229 evaluated guide RNAs in literature would prompt 90% double
strand DNA breaks65. Similar results predicted the inability to shrink viral reservoir size
after evaluating published gRNA sequences against various levels of intrapatient
quasipecies proviral diversity66. To overcome such barriers, algorithmic pipelines that have
been built to identify suitable protospacers in the HIV genome with low risk to
compromising human genes. Evaluation of the platform with both local patient and
nationally annotated proviral sequences revealed four LTR-targeting gRNA combinations
that would prompt >90% excision in 46/48 and 44/48 of cases, respectively67. Further
refinement using patient HIV quasispecies enabled identification of another quadruple
gRNA CRISPR therapy expected to inactivate 96.1% of HIV-1 strains across subtypes68.
These results highlight the potential utility in gRNAs obtained from patient obtained data.
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Figure 1.1 Mechanisms
of CRISPR Treatment
of HIV and Potential
Pitfalls.
(A) Pathways utilizing
CRISPR to halt HIV-1
replication in CD4+ T
cells and mononuclear
phagocytes include (1)
direct
targeting
of
integrated proviral DNA,
(2) ablation of viral entry
(co-)receptors,
and
modulation
of
host
proteins related to (3a)
innate immunity, (3b)
DNA transcription, (3c)
endosomal
processing
that is otherwise hijacked
by HIV-1, and (3d) active
transport. (B) A CRISPRmediated functional cure
for HIV-1 must overcome
barriers such as (1)
potential cleavage of host
genes bearing homology
to HIV-directed guide
RNAs, (2) non-frameshift
mutagenesis of proviral
DNA that may give rise to
CRISPR-resistant HIV-1,
and
(3)
incomplete
delivery of CRISPR to an infected cell population as doing so may prompt (4) viral
breakthrough and re-seeding of anatomic reservoirs with HIV-1.
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1.3.c Ablation of HIV Cellular Entry: Targeting Receptors and Co-receptors
An alternative method of curbing HIV viremia rests in selectively downregulating
viral target cell (CD4+ T cell and monocyte-macrophage) coreceptors employed by the
virus for cellular entry (Figure 1.1A). When glycoprotein 120 (gp120) portions of the HIV
envelope adhere to cellular CD4, a conformational shift in the envelope exposes secondary
ligands that bind cytokine receptors CCR5 or CXCR4. News of functionally cured “Berlin”
and later “London” patients, who received bone marrow transplants from donors carrying
CCR5-Δ32 homozygous mutations that allowed the patients to remain HIV free despite no
longer taking cART, invigorated the prospect that gene therapy could produce similar
outcomes. Early CRISPR studies signaled 4.8 times higher CCR5 editing efficiency than
with TALEN69. Lentiviruses transduced 20% of Jurkat and 11% primary CD4+ T cells
with CCR5-directed CRISPR, which conferred resistance to CCR5 (R5)-tropic HIV
strains70. Editing efficiency further improved to 27% when dual gRNA were utilized to
augment CCR5 expression in induced pluripotent stem cells (iPSC); macrophages
differentiated from these iPSC were likewise resistant to R5-tropic HIV infection in culture
and when challenged in adoptively transplanted humanized mice71. However, when CCR5
ablation was attempted using CRISPR in an HIV+ human patient with acute lymphoblastic
leukemia, viral rebound ensued immediately after interrupting antiretroviral therapy71. The
lack of antiretroviral efficacy in this patient likely stems from the low editing rate- 5% of
lentivirus-transduced leukocytes collected from stem cell mobilization. CRISPR-based
point mutagenesis P19A of cxcr4 made CD4+ T cells impervious to CXCR4 (X4)-tropic
HIV infection with no detected off-target editing72,73. Introduction of CXCR4-directed
CRISPR ribonucleoproteins boosted gene editing to 20% in primary CD4+ T cells74 while
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functionally protecting them from X4-tropic HIV infection75. Finally, combination CCR5CXCR4 ablation with CRISPR using a single lentiviral vector made CD4+ T cells
unreceptive to X4- and R5- strains while reducing apoptosis of target cells76,77. Thus,
targeting CRISPR editing toward coreceptors used for HIV cell entry may potentially
protect individuals after acute exposure or serve as adjunct therapy to limit further
dissemination once viral infection has been established.

1.3.d Modulation of Intracellular Signaling Host Antiviral Pathways
HIV hijacks numerous host proteins to promote its own lifecycle78 and augmented
expression of these proteins by CRISPR gene editing can disrupt ensuing infection. Host
proteins susceptible to therapeutic intervention with CRISPR include those involved in
innate immunity, endosomal transport, active transport, and transcriptional regulation
(Figure 1.1A). Immune regulatory components whose downregulation improves anti-HIV
responses include activated leukocyte cell adhesion molecular (ALCAM)79 , ubiquitinspecific proteinase 18 (USP18) which negatively regulates type I interferon responses80
and SAMHD1 in macrophages81, and miR-146a that represses antiviral cytokine
signaling82. CRISPR-based point mutagenesis of TRIM5α and TRIM34, which function in
innate antiretroviral defense, allowed the proteins to recognize key domains on HIV capsid
that normally allow the virus to transverse towards the nucleus undetected83,84. Endosomal
sorting complexes required for transport (ESCRT) machinery remodels plasma membrane
in both host cellular abscission and viral budding. Although ESCRT-II has been
demonstrated to mediate viral egress in the presence of larger gag-pol transcripts85,
CRISPR knockdown of ESCRT-II limited but did not eliminate viral replication86. LEDGF
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is a transcription coactivator utilized by HIV integrase to bind host chromatin for proviral
integration87. Electroporated CRISPR RNPs directed against LEDGF reduced the
infectibility of primary CD4+ T cells by both X4- and R5-tropic HIV strains88. A CRISPR
target screen to identify dispensable host protein alternates for HIV entry receptors
revealed the utility of knocking out tyrosylprotein sulfotransferase 2 (TPST2) and solute
carrier family 35 member B2 (SLC35B2)79. Lastly, metastasis-associated lung
adenocarcinoma transcript 1 (MALAT1) knockdown with CRISPR-Cas9 reduced LTRdriven HIV transcription and replication75. Although research into CRISPR disruption of
host response proteins is largely designed to understand specific cellular pathways, the
application of such findings enriches our understanding of CRISPR-based therapies for
HIV.

1.3.e Optimizing On- Versus Off-Target Effects
Characterizing the therapeutic window of gene editing using CRISPR requires the
thorough evaluation of potential toxicities89 that may accompany any beneficial
antiretroviral effects90. Many of the HIV genome-directed gRNAs have been evaluated for
off-target editing to host gene sequences (Figure 1.1B)91. One study found that 3.6% of
LTR-targeting gRNA retain potential recognition for the human genome, of which 94% of
complementary sequences lie in non-coding DNA or intronic regions91. To experimentally
determine the actual cleavage of host DNA resulting from CRISPR-Cas applications for
HIV, researchers have progressed towards ever-increasingly unbiased evaluations that
consistently fail to demonstrate notable off-target effects. Early analyses utilized Sanger
sequencing of PCR amplified genes selected based on manual mismatch parameters input
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to publicly available gRNA design tools73,92. Qualitative, nonsequencing T7E1 and
Surveyor assays have been likewise applied in screening for host gene disruption in LTRdirected53 and CCR5-targeted CRISPR therapies77, respectively. CIRCLE-seq and Guideseq assays were developed to sequence portions of DNA that retain signatures of Cas9mediated editing; their use in evaluating LTR-directed CRISPR gRNAs also revealed no
discernable off-target cleavge93,94. Whole genome sequencing of primary CD4+ T cells
treated with LTR- or CCR5-targeting guide RNAs likewise concluded that CRISPR
intervention of HIV resulted in no off-target effects55,70. CRISPR therapies for HIV
investigating alterations to the host transcriptome and functional toxicities to transduced
cells describe lack thereof95-97. Although reports of unwanted CRISPR editing arise in the
literature, they remain notably absent in studies evaluating anti-HIV gRNA.

1.3.f Induction of HIV Escape Mutants
Although Cas9 endonuclease cuts both strands of DNA, not all cleavage events
result in HIV inactivation. Double strand breaks are largely repaired by non-homologous
end joining (and homology driven repair to a lesser extent) that occasionally re-ligates in
the original frame. Failure to induce frameshift mutations has been implicated in giving
rise to CRISPR-resistant strains of HIV50,98,99. This likely results as protospacer sequences
in the HIV genome are partially degraded, rendering original gRNA unable to direct Cas9
to cut proviral DNA. CRISPR strategies to combat HIV that rely on a single have also been
shown to prompt viral escape (Figure 1.1B). Explanations include reduced potency of
Cas9-mediated knockdown (lower editing efficiency)100 and selection for HIV
quasispecies with base pair mismatches relative to designed gRNA52,64,101. Similar to
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utilizing combinations of antiretroviral drugs, multiplexing two or more CRISPR guide
RNAs against the HIV genome has emerged as a favored method to minimize opportunities
for viral escape102.

1.3.g CRISPR Delivery
How best to deliver CRISPR to physiologically relevant immunocytes to combat
HIV replication remains a primary question whose answer may facilitate a functional cure.
Modes of CRISPR deployment include transfection, viral-based transduction, and insertion
of naked- or encapsulated Cas9::gRNA ribonucleoproteins (RNP). Transfection of LTRdirected spCas9 into iPSC using the piggBAC transposase system enabled the formation
of macrophages that resisted infection by two HIV-1 strains51. Alternatively,
electroporation of CRISPR RNP into primary CD4+ T cells identified greater editing
efficiencies of CXCR4 and CCR5 as compared to transgene delivery74,75. Modifications of
tracrRNA in RNPs further improved HIV knockdown when LTR- and CCR5-directed
gRNA were utilized in primary CD4+ T cells103,104. Further works have identified “gesicle”
and nanoparticle RNP delivery platforms that boosted Cas9 activity against HIV in cultured
microglia and in the central nervous system after crossing the blood-brain barrier,
respectively105,106. The deployment of CRISPR in these manners offer perhaps the most
direct means of enacting desired activities in target sites.
Yet, viral transduction of CRISPR-Cas9 encoding transgenes via viruses remains a
common approach in evaluating such therapies for HIV. Prime advantages to utilizing
lentiviruses are their high transduction efficiencies and ability to stably knockin transgenes.
Lentiviruses have been utilized for delivering CRISPR systems targeting LTR55,
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gag/pol107, CCR597 and CXCR4108. Engineering of Lenti/saCas9 systems with shorter
CRISPR transgenes than conventional spCas9 helped overcome concerns of low potencies
and transduction potentials in CD4+ T cells100,108. Alternatively, surface decoration of
lentiviruses with recombinant tat protein enables adoptively transferred monocytes to cross
the blood-brain-barrier and reduce HIV in the CNS109. Adenovirus offers the ability to
deliver non-integrating CRISPR transgene, though one limitation is their low transduction
efficiencies. CCR5-directed gRNAs were expressed in 11.8% of easily transducible A549
human lung carcinoma cells at multiplicity of infection (MOI) 10. Nonetheless, Ad5F35
adenoviral vectors have demonstrated the ability to successfully deliver CCR5-targeting
CRISPR to CD4+ T cells resulting in protection from HIV infection97,110. Finally, adenoassociated virus (AAV) is a lowly immunogenic vector with limitations in both the size of
transgene capacity and in vitro transduction efficiency. It has been successfully deployed
for HIV in vitro using CXCR4, LTR-, and LTR/gag-targeting Cas9 guide RNAs108,111. The
latter system also demonstrated reliable in vivo transduction in 5 organs and blood from
HIV model organisms112. In summary, the advantages of and utility of each viral vector
system in treating HIV with CRISPR will become increasingly clear as research continues.

1.3.h HIV Elimination Using CRISPR
A limited number of studies have aimed to demonstrate proof-of-concept for HIV
elimination via CRISPR-Cas therapy. Unlike CCR5 ablation that results in a functional
cure, meaning that hosts no longer rely on antiretroviral drugs to repress HIV replication,
CRISPR-targeting of the HIV provirus presents the potential for a sterilizing cure- one in
which all traces of latent viral DNA and RNA are removed. An extensive evaluation of
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lentiviral transduced LTR-directed Cas9 therapy revealed full-length excision of proviral
DNA between in a latently infected CD4+ T cell line, complete protection from de novo
HIV-1NL4-3 infection in PBMC isolated CD4+ T cell cells, and >80% reduction in HIV+
patient isolated PBMC treated ex vivo55. In this study, stimulation of latently infected T
cell line with PMA failed to reverse latency, further evidencing complete inactivation of
proviral DNA via CRISPR. Subsequent testing of Cas12a showed that although greatest
knockdown was observed in a transfection screen with LTR-directed crRNA, Tat- or
Tat/Rev-targeting crRNA led to higher degrees of complete viral suppression from
chronically infected SupT1 CD4+ T cells54. Cultures remained free of viral breakthrough
for 60 days with these targets, suggesting definitive cleavage at vital loci in the proviral
genome. These works set the stage for evaluating the curative potentials of CRISPR
therapies applied to infected cells.
Two seminal studies describe the utility of CRISPR-Cas9 in eliminating HIV
entirely from infected hosts. Firstly, lentivirus was used to transduce LTR- U3 directed
spCas9 therapy in NOD/SCID mice that were transplanted with PBMC from HIV-infected
human patients. Results showed lentivirus eliminated the presence of viral DNA fragments
from blood and three major reservoir sites of infected animals113. Secondly, a CD34+
huHSC reconstituted (“humanized”) mouse model was employed to simulate how direct
infection with HIV-1 might be sterilized. After the establishment of X4-tropic HIV-1NL4-3
or R5-tropic HIV-1ADA, animals were treated with a combination of nanoformulated longacting slow effective release antiretroviral (LASER ART) prodrugs to induce maximal
viral latency and full suppression of viral replication. Thereafter, rAAV9/LTR-Gag dual
saCas9 gRNA therapy was administered. The data set demonstrated that a third of LASER

22

ART + CRISPR treated animals were sterilized of HIV as determined by highly sensitive
molecular diagnostics and functional viral outgrowth assays114. Together, these efforts
signal that CRISPR therapy has evolved from a research tool to one with capacity to cure
human disease.
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1.4 Considerations for Designing CRISPR-Cas9 Nanoparticles for HIV-1 Elimination
The success of HIV-1 elimination in humanized mice using adeno-associated virus 9 (AAV9) and
lentivirus must be tempered with an understanding of the challenges that lay ahead in translating
similar CRISPR therapies to humans. Firstly, AAV’s low transduction efficiency115 necessitates
treatment with high volumes of virus116. In contrast, lentiviruses retain comparatively high
transduction efficiencies117 but raise safety concerns of the indiscriminate integration of transgene
in host nuclei. Second, host immunogenicity against viruses risks neutralizing these therapies
before CRISPR is deployed. This remains highly problematic as HIV-positive patients retain antilentiviral antibodies in circulation118. Finally, any viral vector must adequately reach every HIVinfected cell in all tissues to achieve curative sterilization. In light of these challenges, CRISPRCas9 nanoparticles represent an ideal platform that can be engineered to the rigorous specifications
required for an HIV-1 curative strategy.
CRISPR nanoparticles have been previously designed to bypass payload clearance.
Systemically-administered CRISPR can be in DNA form (as with AAV transgene), RNA form (as
with lentiviral transgene and mRNA therapeutics), or ribonucleoprotein. The latter consists of
recombinant Cas protein that is pre-complexed with synthetic guide RNAs (gRNAs) against a target
of interest. Regardless of which form CRISPR is in, nucleic acids must be shielded from circulating
nucleases present in the blood stream119. In addition, CRISPR biologics must be purified from
endotoxin to avoid immune-based clearance120. Nucleic acid-bearing nanoparticles should also
measure larger than 6 nm to avoid renal clearance121,122. To neutralize the surface charge of both
nucleic acids and proteins, as is required to bypass cell membranes, two nanoparticle platforms
exist. Nanocapsule CRISPR nanoformulations first neutralize surface charges with cationic or
anionic monomers, then generate a shell of biodegradable imidazole and glutathione-containing
cross-linkers123. Nanoclews124, lipoplexes125, and imidazole frameworks126 all employ similar
modes of spontaneous assembly that drive their synthesis. Advantages to this approach are that
imidazole facilitates endosomal escape once endocytosed while glutathione oxidation in the cytosol
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releases CRISPR RNP to then traffic to the nucleus. However, variability in the size, uniformity,
and stability of such formulations risk hampering consistent gene editing required for therapeutic
efficacy. Lipid nanoparticles (LNP) stand as alternatives to nanocapsules. LNPs for CRISPR
delivery utilize ionizable cationic lipids to complex with charged nucleic acids within, and
zwitterionic phospholipids, cholesterol, and polyethylene glycol (PEG) lipids as encasements127.
Lipid shells thus carry payloads across lipid bilayers, while the ionizable lipids and phospholipids
rupture the particles once they reach acidic endosomes.
CRISPR nanoparticles can be finely tuned for targeting particular tissues. Decoration of
CRISPR RNP nanocapsules with all-trans retinoic acid (ATRA) facilitated significant editing of
retinal pigmented epithelium, a notoriously hard to target tissue, in transgenic mice123. Inclusion of
permanently cationic-, permanently anionic-, or ionizable lipids in LNP shells facilitated selective
delivery to CRISPR LNPs to lungs, spleen, or liver, respectively128. Metal cores may also serve as
scaffolds within LNPs. Gold nanoclusters have been used to deliver CRISPR RNPs that suppress
melanoma progression129 and lower LDL-C cholesterol in mice130. Inclusion of paramagnetic
materials in CRISPR RNP nanoparticles even facilitated magnetic guidance of HIV-1 proviral
cleaving therapy to microglia in the brain106. Thus, CRISPR nanoparticles can be tailored on their
surfaces or at their cores to meet user-defined needs.
Tools that aid in therapy and diagnosis, termed “theranostic”, have enabled intelligent
design of nanoparticle treatments for various disease processes, including HIV-1 infection.
Inclusion of paramagnetic materials like europium and ferrite in antiretroviral theranostics has
enabled non-invasive real-time tracking by magnetic resonance imaging (MRI)131,132. More
sensitive imaging techniques, like single photon emission computed tomography (SPECT-CT), can
also be performed by supplementing radioactive tracers, such as lutetitium-177 (177Lu), in
theranostics that model the biodistributions of nanoformulated antiretrovirals (nanoART)133,134.
Tracing particle migration in real-time not only reduces the need to sacrifice animals, but enables
accurate predictive models to be established of where therapeutics will deposit at future time
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points133. With these tools already in place and guiding the development nanoformulated
antiretrovirals, applying theranostics to the nascent field of CRISPR nanoparticle delivery stands
as the logical progression in the quest for an HIV-1 cure.
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CHAPTER 2
Exonic Disruption Facilitates
Antiviral CRISPR-Cas9 Activity for Multistrain HIV-1 Elimination

2.1 ABSTRACT

A barrier to HIV-1 cure rests in the persistence of proviral DNA in infected CD4+
leukocytes. The high mutation rate of HIV-1 gives rise to numerous circulating strains with
increased capacity for immune evasion and antiretroviral drug resistance. To facilitate viral
elimination while accounting for this diversity, we propose genetic inactivation of proviral
DNA with CRISPR-spCas9. We designed a library of “mosaic gRNAs” against a HIV-1
consensus sequence constructed from 4004 clinical strains, targeting the viral
transcriptional regulator tat. Testing in 7 HIV-1 transmitted founder strains led, on average,
to viral reductions of 82% with tandem TatD and TatE (TatDE) treatment. No off-target
cleavages were recorded. Lentiviral transduction of TatDE attenuated latency reversal by
94% in HIV-infected, transcriptionally silent ACH2 T cells. In all, TatDE guide RNAs
successfully disrupted 5 separate HIV-1 exons (tat1-2/rev1-2/gp41) providing a pathway for
CRISPR-directed HIV-1 cure therapies.
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2.2 INTRODUCTION
Defining the scientific pathways required to eliminate the human immunodeficiency virus
type one (HIV-1) from its infected human host remains a global health concern for 38
million infected people. The potential for HIV-1 reactivation from latent integrated proviral
DNA in CD4+ T cells and mononuclear phagocytes requires lifelong antiretroviral therapy
(ART). ART protects against virus-induced reductions in numbers and function of CD4+
T lymphocytes and progression to the acquired immunodeficiency syndrome (AIDS)135.
Thus, a functional cure for HIV-1 is needed which would eliminate any dependence on
lifelong ART. Various approaches toward this goal have generated international attention
in the scientific community but have yet not been realized5.
While curative measures for HIV-1 are under development, gene editing stands
alone by having the ability to remove virus independent from host antiviral adaptive
immunity. Although concurrent viral elimination strategies that include broadly
neutralizing antibodies (bnAbs)136, immune modulation137, and chimeric antigen receptor
(CAR)-T cells138,139 show promise, they also retain limitations. These include the selection
for bnAb resistant strains140, viral rebound137,141, and adverse side effects142. All have been
reported in monkeys and humans. Treatments notably depend on host FcR-mediated
cellular killing or antigen presentation in MHC-I and as such and rely on host immunity
for viral clearance. CD4+ T cell exhaustion can also limit the clinical translatability of
bnAbs. Thus, the potential of gene therapy has emerged as a promising new research area
in its ability to deplete HIV-1 infected cells by directly targeting either host receptors or
HIV-1 proviral DNA itself. As for the former, the viral co-receptor CCR5 can be ablated
ex vivo143,144 while latent viral DNA can be excised in live animals145. Based on these

28

results gene therapy for HIV-1 elimination is under active clinical investigation (e.g.
NCT02140944, NCT03164135, NCT03666871).
Nonetheless, applying gene therapy towards HIV-1 cure strategies has met a
number of obstacles. One of the most significant rests in viral DNA sequence diversity.
With a mutation rate of 1 in 1700 nucleotides146, HIV-1 quasispecies easily accumulate
during the course of viral infection147. Divergent strains with increased replicative fitness
evade host immunity in individuals and through populations147 as evidenced by the
emergence of 11 global HIV-1 subtypes (also referred to as clades; A-L)148. HIV-1
subtypes B and C are the most prevalent clades in Europe / the Americas (10.2%)149 and
worldwide (46%)150, respectively. Thus, gene therapies designed to target then eliminate
HIV-1 must overcome strain diversity.
We posit that clustered regularly interspaced short palindromic repeat (CRISPR)
approaches can meet the challenge of viral diversity through their abilities to pair genetic
precision and engineering. CRISPR employs single guide RNAs (gRNAs) to program
CRISPR-associated protein (Cas) endonucleases48 providing complementarity between
user-selected RNA and target DNA “protospacer” regions of DNA. Potential subgenomic
proviral DNA targets of the 10 kilobase pair (kb) HIV-1 genome include the viral promoter
LTR51-54 and viral transcription factor tat61,62,151. CRISPR gene editing can be facilitated
by applying it to two alternatively spliced HIV-1 tat exons. In this way it can retain an
ability to simultaneously cleave rev and env that are transcribed from same portion of the
genome but in alternate open reading frames61.
Defining the optimal gRNAs, alone or in combination, to eliminate HIV-1 infection
and implementing the approach to human trials is a challenge. First, computational
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assessments suggest that any choices require affirmation in patient derived HIV-1 isolates.
Indeed, previously published LTR-targeting guide RNAs likely possess limited cleavage
efficiencies during natural infection65. Second, gRNAs musts inactivate HIV-1
transcription precluding the assembly of functional virions en trans from intact viral
operons. Third, optimal combination gRNAs must minimize any emergence of CRISPRresistant escape mutants54,151 in order to affect maximal editing. While multiplexed
CRISPR-Cas9 treatments were designed to account for HIV-1 strain variation68 and
minimize viral escape61 testing against transmitted founder viral strains was not completed.
Fourth, any CRISPR-Cas9 delivery system seeking to find and eliminate virus from its
natural target cells must be employed.
Accepting each of these needs, we developed then characterized a CRISPR-Cas9
system capable of eliminating diverse proviral HIV-1 strains. The approach taken mirrors
the “mosaic” HIV-1 vaccine design currently in late phase clinical trials (NCT03964415,
NCT03060629) serving to immunize those person with a high risk of acquiring infection
with HIV-1 gag/pol/env antigens encoded from global composite viral strains152. The data
offered supports the concept that CRISPR-Cas9 guide RNAs designed against a multiclade
HIV-1 consensus sequence, hereafter termed “mosaic gRNAs”, can prove effective. The
mosaic gRNAs targeting genetically conserved and overlapping tat/rev exons maximized
CRISPR-based attenuation of HIV-1 infection. A lentiviral transduced CRISPR-Cas9
system proved successful in its ability to block HIV-1 reactivation from latently infected
CD4+ T cells. The data, taken together, brings the approach one step closer towards
defining a workable strategy for HIV-1 cure.
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2.3 RESULTS

2.3.a In silico design of HIV-1 tat mosaic gRNAs
Targeted HIV-1 gene therapy requires specific recognition of diverse proviral
sequences. HIV-1 sequence diversity occurs both at the population level and during disease
progression within an infected host affecting host immune responses and antiretroviral drug
resistance 153. While the 5’ long terminal repeat (LTR) is a promoter for viral transcription
and is susceptible to CRISPR-based HIV-1 inactivation we reasoned that targeting the
driver of LTR-directed transcription, HIV-1 tat, would improve CRISPR therapeutic
efficacy. To test this, a multiple sequence alignment heat map, constructed from 4004 HIV1 strains, was utilized to observe the degree of nucleotide heterogeneity across the ~10kb
viral genome (Figure 2.1). Conserved regions of the HIV-1 genome include portions of
flanking LTRs, gp120-encoding segments of env, and multiple exon overlaps (Figure
2.1A). Low entropy in HIV-1 genes encoding p6 / protease, tat / rev, vpu / gp120, and nef
/ 3’ LTR highlight sequence preservation in loci that govern multiple phases of the viral
lifecycle.
As comparators, two CRISPR-Cas9 reference systems were adopted. First, LTR-1
and GagD are guide RNAs (gRNAs) that target the U3 portion of LTR and MA region of
gag, respectively (Figures 2.1B, 2.1D). LTR-1/GagD was selected as a reference control
because of its utility in sterilizing one-third of HIV-1 infected humanized mice, thereby
establishing proof-of-concept for a CRISPR-based HIV cure in vivo 145. Second, DLTR-1
and DLTR-2 are the top-rated gRNAs from a quadriplex panel designed to cleave a high
percentage of known HIV-1 strains with minimal off-target human genome recognition 68.
Delivery of DLTR-1 and DLTR-2 gRNAs to cells remains a challenge, however, because
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their targeting of HIV-1 LTR (Figure 2.1D) simultaneously also thwarts the synthesis of
all CRISPR-transducing lentiviruses. Control gRNAs display complete 20 base pair (bp)
recognition of 11-30% of curated HIV-1 strains (Table 2.1). Minimum off-target threshold
of 2.266 was set for tat gRNA design in accordance with a CRISPR-specificity algorithm
score for the DLTR-2 control.
A library of eight HIV-1 tat-targeting gRNAs designed for deployment with
Streptococcus pyogenes Cas9 (spCas9) endonuclease were created to maximize the
curative potential of our CRISPR system. These “mosaic” gRNAs were constructed against
the tat consensus sequence synthesized from 4004 HIV-1 strains (Figure 2.2). Five of the
eight produced gRNAs target the sense strand (Figure 2.1C). Because portions of tat
overlap with rev and the gp41 portion of env, up to three exons could be simultaneously
disrupted with these gRNAs (Figure 2.1D). Notably, tat-directed gRNAs retain full 20 bp
complementarity for 6-67% of all known HIV-1 strains (Table 2.1). Taken together, these
data demonstrate that gRNAs can be produced with broad HIV-1 excision potential while,
at the same time, limiting off-target effects.
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Figure 2.1

Figure 2.1. HIV CRISPR-Cas9 Mosaic gRNA in silico Design.
(A) Nucleotide heterogeneity of 4004 annotated HIV-1 strains is depicted in heat-map form
demonstrating entropic (blue) or conserved (red) loci in all 3 reading frames. (B-C)
Previously reported gRNA against LTR- and gag regions, used herein as reference controls
(B) or novel gRNA targeting mosaic tat sequences of HIV-1 (C) were designed. gRNA
against antisense or sense sequences are shown as downward or upward facing arrows,
respectively. (D) Guide RNAs directed against HIV-1 LTR / gag (red) or tat exons
overlapping with up to two additional genes (green) were designed using and HIV-1
consensus sequence.
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Figure 2.2

Figure 2.2. CRISPR-Cas9 Targeting HIV-1 tat Consensus Sequence.
Sequence logos depicting loci of spCas9 gRNA targeting HIV-1 tat exon 1 (nucleotide
positions 5831-6045 using HIV-1HXB2 reference strain) and tat exon 2 (nucleotide positions
8379-8469) amongst all curated HIV-1 strain sequences compiled as of 2018 (n = 4004;
http://www.hiv.lanl.gov/) were generated using WebLogo v3.7.4. Conserved nucleotides
are represented as taller letters whereas blank spaces denote frequent gaps in alignment.
gRNA directed against sense or antisense strands are shown as rightward (green) or
leftward (red) facing arrows, respectively.
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Table 2.1. Mosaic gRNA Target Conservation and Specificity
% Sequence
gRNA Name
Target DNA Sequence (5’ à 3’)
Conservation
(n = 4004)
LTR-1 (control) GCAGAACTACACACCAGGGCC
27.12 %

iii

CRISPRspec
Score‡iii
6.937

GagD (control)

GATAGATGTAAAAGACACCA

11.14 %

4.071

DLTR-1 (control)

GACTGCTTAAGCCTCAATAA

29.57 %

3.364

DLTR-2 (control)

GCTTTATTGAGGCTTAAGCAG

28.94 %

2.266

TatG

TCTCCGCTTCTTCCTGCCAT

67.15 %

3.803

TatD

TCTCCTATGGCAGGAAGAAG

59.04 %

6.284

TatH
TatA2

GCTTAGGCATCTCCTATGGC

51.12 %

4.662

TAGATCCTAACCTAGAGCCC

29.79%

7.327

TatI

GGCTCTAGGTTAGGATCTAC

25.90 %

6.844

TatE

GAAGGAATCGAAGAAGAAGG

15.26 %

3.090

TatF
TatE2

CCGATTCCTTCGGGCCTGTC

6.19 %

6.467

GAAAGAATCGAAGAAGGAGG

5.82 %

6.021

CRISPRspec score represents the specificity of the selected gRNA for HIV-1 based on a
predefined off-target landscape within the human genome. Calculated using CRISPROFF
webserver v1.1.
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2.3.b Tat/rev-directed gRNAs suppress HIV-1 replication
To test the hypothesis that conserved gRNA would most effectively limit viral
replication, a plasmid co-transfection screen was implemented. Human embryonic kidney
(HEK293FT) cells were transfected with plasmids encoding HIV-1 in the absence
(untreated control) or presence of spCas9-gRNA constructs. Seven HIV-1 molecular
clones, one laboratory (NL4-3) plus six clade B founder strains, were included to reflect
predominant North American and European viral subtype sequence heterogeneity.
Supernatants were measured after 72 hours by reverse transcriptase (RT) activity assay.
The RT assay avoids strain-dependent antibody-epitope recognition otherwise encountered
by enzyme linked immunosorbent assays (ELISA).
The single gRNA CRISPR TatE and TatD constructs demonstrated the greatest
suppression of HIV-1 replication (Figure 2.3A). TatE gRNA reduced RT activity by an
average of 76% (± 6.5%, standard error of the mean (SEM)), with more than 75% reduction
in 6 of 7 tested HIV-1 strains. Notably, TatE outperformed all single gRNA controls,
including DLTR-2, which demonstrated a 59% (± 7.0% SEM). TatD likewise displayed a
high degree of proviral DNA viral inactivation, with a mean RT activity reduction of 54%
(± 5.1%, SEM). Pearson correlation analysis evaluated whether CRISPR gRNA activity
was associated with target sequence conservation (Figure 2.3B). While positive trends
were observed significance was achieved when TatE was excluded from analysis. The data
support the idea that although gRNA targeting conserved genomic regions of HIV-1
proviral DNA are generally more efficacious, the TatE locus is critical to viral replication.
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Figure 2.3

Figure 2.3. TatDE Dual gRNAs Facilitate Multistrain HIV-1 Excision.
(A) A gRNA library was screened against multiple HIV-1 molecular clones via cotransfection of HEK293FT cells for reduction in viral replication as measured by reversetranscriptase (RT) activity assay. (B) Pearson correlation between gRNA target
conservation among 4004 proviral DNA sequences and average RT activity knockdown
was assessed. (C) PCR was performed on DNA extracted from (A) to PCR amplify
untreated- or CRISPR-TatDE plasmid-treated cells. White arrow indicates expected
molecular size of TatDE excision bands. (D) Excision bands from (C) reaction contents
were Sanger sequenced and subjected to Inference of CRISPR Edits v2.0 (ICE, Synthego
2020) to visualize nucleotide editing in the PAM/protospacer region; total
insertion/deletion (indel) and knockout percentages determined by ICE are listed alongside
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tracings. Data in (A-B, E) depict mean ± SEM from four independent experiments each
containing biological triplicates.
We next sought to determine whether proviral DNA excision induced by two
CRISPR-Cas9 gRNA would provide additive or synergistic effects in suppressing HIV-1
replication. The noted efficacy of TatE, which targets a region of tat that overlaps with
both rev and env, prompted us to posit that simultaneous disruptions of multiple viral exons
would most drastically blunt HIV-1’s lifecycle. Plasmids were subcloned to express
various combinations of our top three performing tat-directed gRNAs. Table 2.2
summarizes the percent conservation, excision fragment length, and number of deactivated
exons elicited by each pairing. Increased antiretroviral activity was observed when TatD
and TatE gRNAs were co-expressed (TatDE). Viral replication in TatDE-treated cells were
lowered on average by 82% (± 4.6%, SEM), with a range of 65-98% across all tested viral
strains (Figure 2.3A). TatDE demonstrated greater levels of viral suppression compared to
LTR-1/GagD (“LG”) and DLTR-1/DLTR-2 (“DLTR1-2”) duplexed reference CRISPR
controls by measured RT activity. Of note, combining DLTR-1 and DLTR-2 reduced
gRNAs’ antiviral activities. This was posited to be due to steric hindrance of Cas9
endonuclease as the gRNAs bound in close proximities to each other. The ~2.5 kilobase
pair (kb) dropout of intervening proviral DNA was observed against all seven HIV-1
molecular clones (Figures 2.3C, 2.4). To confirm the accuracy of TatDE CRISPR, excision
bands were Sanger sequenced and analyzed by Inference of CRISPR Edits (ICE) algorithm
(Figure 2.3D). Sequencing data qualitatively depict nucleotide degeneracy in both target
loci, with insertion/deletion (indel) mutations at a rate of 25-51% in excision bands.
Assessment of the most-conserved pairing, TatDH, and largest excising duplex, TatEH,
proved inferior to TatDE in suppressing RT activity (Figure 2.3A). This was observed as
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TatDE targets 5 viral exons. In contrast, TatDH and TatEH inactivate 3 and 4 viral exons,
respectively. Taken together, these data support the notion that disrupting a maximal
number of viral exons by CRISPR-Cas9 leads to the greatest suppression of HIV-1
replication.

Table 2.2. Mosaic gRNA Coverage
gRNA Name
TatD

59.04 %

-

2

TatH§iv

51.12 %

-

1

TatE

15.26 %

-

3

TatDH

59.44 %

29

3

TatDE

62.19 %

2442

5

TatEH

56.24 %

2451

4

‡v

iv §

% Sequence Conservation
Excised Base Pairs Exons Disrupted
(n = 4004 HIV-1 Strains)

4 base pairs of TatH gRNA overlap with rev. Given that CRISPR cleavage, as
determined by ICE, occurs 5+ bp distal to PAM, TatH was considered to disrupt 1 exon
(tat).

v ‡

Although TatDH is a composite of 2 highly conserved gRNAs, they overlap in target
recognition and therefore multiplexing did not significantly increase breadth of coverage.
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Figure 2.4

Figure 2.4. TatDE Dual gRNA Facilitate Multistrain HIV-1 Excision.
HEK293FT cells co-transfected with pHIV-1 in the absence or presence of CRISPR-gRNA
containing plasmids were assayed by PCR for DNA excision of 2.461 kb between
intervening protospacers contained in tat/rev. Arrow indicates expected molecular size of
TatDE excision-band.
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2.3.c On-target CRISPR-Cas9 TatDE specificity
We next evaluated the specificity of our tat-directed CRISPR-Cas9 by comparing
the degree of proviral genome editing to that observed in off-target loci. DNA extracted
from our co-transfection screen was PCR amplified in regions corresponding to 5’ LTR –
gag (control) or tat exons 1 and 2. Sequencing was performed on all 7 HIV-1 clones for
TatD, TatE, and TatDE treatments, while a more focused study of DNA from 4 HIV-1
strains was included for remaining groups. ICE analysis performed on Sanger sequences
from these reactions revealed that dual gRNA systems improve indel mutation rates to
>40% as compared to <10% seen with single gRNA controls (Figure 2.5). Mean editing
was 10.1% (±7.5%, SEM) and 2.3% (±1.5%, SEM) for TatE and TatD, respectively. In
contrast, TatDE therapy resulted in an average of 45% (±3.0%, SEM) mutagenesis with
40-50% editing in 6 of 7 tested strains. We conclude that a small percentage editing of tat
by CRISPR-Cas9 elicits substantive viral suppression as exhibited by TatD treatment.
Conversely, TatE2 and TatF which report up to 10-13% indel rates failed to influence HIV1 suppression level in our functional screen. We also observe that multiplexing TatD and
TatE led to consistently high rates of mutagenesis, supporting TatDE’s ability to deactivate
a broad variety of HIV-1 proviral species.
As the therapeutic window of CRISPR targeting HIV-1 proviral DNA is based in
equal measure to TatDE off-target cleavage in the human genome, we investigated the
potential for aberrant indels. These covered 5 possible loci recognized by each TatD, TatE,
LTR-1, and GagD. Four of the highest ranked off-target loci predicted by CRISPRoff for
base pair mismatching and one candidate site accounting for gRNA internal bulging via
Cas-OFFinder were selected for ICE analysis. At all putative off-target positions for TatD

41

and TatE, no editing was observed (Tables 2.3-2.4). This was sustained regardless of
whether cells were treated with a single or dual gRNAs. Similarly, off-target analysis by
ICE for LTR-1 and GagD failed to demonstrate indel mutations in host genes (Tables 2.52.6). Seven of 10 possible off-target regions for TatDE fell in intronic regions whereas only
2 of 10 for LTR-1/GagD were noncoding. Though this could be a sampling bias from
selection of only 10 off-target loci, it reinforces the notion that TatDE CRISPR is not more
likely to affect host gene expression than other operative HIV-1 CRISPR systems.
Figure 2.5
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Figure 2.5. TatDE dual gRNA CRISPR facilitates high on-target gene editing.
DNA from pHIV-1 co-transfected HEK293FT cells treated with single- or dual-gRNA
expressing plasmids was PCR amplified and subjected to ICE analysis to determine
insertion / deletion (indel) percentages in the vicinity of PAM/protospacer for n ≥ 4 HIV1 molecular clones. Results are from pooled biological triplicates from a representative
gRNA screen. Bars represent mean ± SEM.
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Table 2.3: Off-Target TatD CRISPR Editing

gRNA

Guide Target
(Protospacer mismatches) + PAM

Gene
(Locus)

CCTCCCATGGCAGAAAGAAGT
GG

ALDH3B1
(11q13.2)

CTTCCCACGGCAGGAAGAACC
GG

GPC6
(13q31.3q32.1)

Treatment

pHIV-1 Molecular Clone
pCH04 pCH10
pCH05
pTHRO
0.c/262 6.c/263
8.c/296
.c/2626
5
3
0

TatD

0%

0%

0%

0%

TatDE

0%

0%

0%

0%

TatD

0%

0%

0%

0%

TatDE

0%

0%

0%

0%

TatD

0%

0%

0%

0%

TatDE

0%

0%

0%

0%

TatD

0%

0%

0%

0%

TatDE

0%

0%

0%

0%

TatD

0%

0%

0%

0%

TatDE

0%

0%

0%

0%

TatD
CTTCCTAGGGCAGGAAGAAGG
GG

IGFBP5
(2q35)

TTCTCCTAGGAAGGAGGAAGA
GG

Intronic
(12q24.33)

AATCTTATGGCAGGAAGAAGA
GG

Intronic
(9q22.2q31.1)

Gene Function
Aldehyde
dehydrogenase aids in
alcohol metabolism
and lipid peroxidation
(Accession
NG_012282)
Glypicans encode cell
surface coreceptors for
control of cell growth
and division
(Accession
NG_011880)
Insulin-like growth
factor-binding protein
5; function in humans
under characterized
(Accession
AC007563)
(Accession
AC127071)
(Accession AL137847)
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Table 2.4: Off-Target TatE CRISPR Editing

gRNA

TatE

Guide Target
(Protospacer mismatches) + PAM

Gene
(Locus)

GAAGAAAACAAAGAAGAAGGA
GG

Intronic
(18q12.2)

GAAGGAAGAGAAGAAGAAGG
AGG

Intronic
(19q13.33)

GAAGGAATCAAGAAGAAGGAGG

Intronic
(4q35.1)

GAAAGGAAGGAAGAAGAAGG
GGG

Senescenc
e gene
region
(8p11.2)

AAAGGAATCGAAGAAGAAGGG
GG

Intronic
(7q31.33)

Treatment

pHIV-1 Molecular Clone
pCH04 pCH10
pCH05
pTHRO
0.c/262 6.c/263
8.c/296
.c/2626
5
3
0

TatE

0%

0%

0%

0%

TatDE

0%

0%

0%

0%

TatE

0%

0%

0%

0%

TatDE

0%

0%

0%

0%

TatE

0%

0%

0%

0%

TatDE

0%

0%

0%

0%

TatE

0%

0%

0%

0%

TatDE

0%

0%

0%

0%

TatE

0%

0%

0%

0%

TatDE

0%

0%

0%

0%

Gene Function

(Accession
AC118757)

(Accession
AC010330)

(Accession
AC079080)

(Accession
AP000078.1)
(Accession
AC005521)
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Table 2.5: Off-Target LTR-1 CRISPR Editing

gRNA

Guide Target
(Protospacer mismatches) + PAM
GCAGAACCACTCCCCAGGGCCT
GG

AAAGAACAACACACCAGGGAG
GGG

LTR-1

TAAAAACTACACACAAGGGCC
AGG

Gene
(Locus)
GRIK3
(1p35.1)

Treatment

pHIV-1 Molecular Clone
pCH04 pCH10
pCH05
pTHRO
0.c/262 6.c/263
8.c/296
.c/2626
5
3
0

LTR-1

0%

0%

0%

0%

LG

0%

0%

0%

0%

LTR-1

0%

0%

0%

0%

LG

0%

0%

0%

0%

LTR-1

0%

0%

0%

0%

LG

0%

0%

0%

0%

LTR-1

0%

0%

0%

0%

LG

0%

0%

0%

0%

LTR-1

0%

0%

0%

0%

LG

0%

0%

0%

0%

CADPS2
(7q31.31)

Intronic
(3q13.32)

AGGGAAACACACACCAGGGCC
AGG

GP6C
(13q31.1)

TAGAACTACACCACCAGGGCC
CGG

CRX
(19q13.33)

Gene Function
Glutamate ionotropic
receptor kainate type
subunit 3; glutamate
neurotransmitter receptor
subunit. (NG_011447.1)
Calcium dependent
secretion activator 2;
regulates exocytosis of
synaptic vesicles in
neurons and
neuroendocrine cells.
(NG_016215)
(Accession AC021889)
Glypican 6;
glycosphlphophatidylinosit
ol-anchored proteoglycan
implicated in cell growth
and cell division.
(NG_011880.1)
Cone-rod homeobox; plays
role in differentiation of
photoreceptor cells and
maintenance of cone & rod
function. (AC008745.7)
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Table 2.6: Off-Target GagD CRISPR Editing

gRNA

Guide Target
(Protospacer mismatches) + PAM

CACAGAGGCAAAAGACACCAT
GG

GagD

Gene
(Locus)
otopetrin 1
pseudogen
e
(2p11.2)

GATAGATGTAAAAGACACTGT
GG

ZNF420
(19q13.41)

GATAGATGTAAAAGACACCAG
GG

MLLT3
(9p22.1)

GAGAAATATAAAAGACACCAT
GG

Intronic
(5q22.2)

TATAGCTGTAAAAACACCAAGG

n.d.: no data available

Treatment

pHIV-1 Molecular Clone
pCH04 pCH10
pCH05
pTHRO
0.c/262 6.c/263
8.c/296
.c/2626
5
3
0

GagD

0%

0%

0%

0%

LG

0%

0%

0%

0%

GagD

0%

0%

0%

n.d.

LG

0%

0%

0%

n.d.

GagD

0%

0%

0%

0%

LG

0%

0%

0%

0%

GagD

0%

n.d.

0%

0%

LG

0%

n.d.

0%

0%

GagD

0%

0%

0%

0%

LG

n.d.

0%

0%

0%

PTPRG
(3p13.2)

Gene Function
Nonfunctional DNA
segment derived from
OTOP1 (4p16.3), a
gene that is required
for the formation of
inner ear otoliths.
(NG_021568.4)
Zinc finger protein
420; negatively
regulates p53-mediated
apoptosis especially in
testes and ovaries.
(AC008733.9)
MLLT3 super
elongation complex
unit. (AK512635.8)
(Accession
AC137549.1)
Protein tyrosine
phosphatase receptor
type G; signaling
molecule in mitosis,
differentiation, and
oncogenic
transformation.
(AC092502.2)

46

2.3.d TatDE CRISPR-Cas9 eliminates latent proviral HIV-1
Having demonstrated the ability of TatDE CRISPR to suppress plasmid-encoded
viral transcription, we next investigated whether latent HIV-1 could be excised in
leukocytes. For these experiments, TatD, TatE, or non-targeting control gRNAs were
cloned onto a lentiviral-CRISPR expression plasmid. To first assess CRISPR-Cas9
function, ACH2 T cells and U1 promonocytes bearing 1-2 copies of latent HIV-1 proviral
DNA copies per cell were transfected with cloned lentiviral CRISPR constructs.
Subsequent stimulation of ACH2 cells with TNFα induced viral rebound in control- and
LTR-1/GagD-treated cultures but not in those receiving single- or dual TatD plus TatE
treatments (Figure 2.6). U1 promonocytes were equally susceptible to LTR-1 / GagD and
TatD / TatE treatments (Figure 2.7). HIV-1 proviral DNA excision was present in both
cell types and confirmed by sequencing. These data in aggregate validate the TatDE
CRISPR-Cas9 system for lentiviral delivery.
We next ascertained whether lentiviral transduction of TatDE CRISPR-Cas9 could
halt HIV-1 induction from latently infected ACH2 T cells. ACH2 were transduced with
CRISPR at multiplicities of infection (MOI) of 10, 1, or 0.1 transducing units/cell for 3
days followed by tumor necrosis factor alpha (TNFα) stimulation. spCas9 transgene
expression was measured by reverse-transcriptase quantitative PCR (RT-qPCR) and
determined to be above detection limits (Figure 2.8A). Under these conditions, untreated
controls and ACH2 transduced with non-targeting gRNA resulted in synthesis of progeny
virions after TNFα stimulation (Figures 2.8B-C). All dual TatD/TatE lentiviral treatments
blocked TNFα-induced stimulation. Co-transduction of TatD/TatE at MOI 10 and 1
significantly reduced the release of HIV-1 into culture supernatants by 80% and 94%
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respectively. We also evaluated cell DNA by nested PCR for TatDE HIV-1 excision
(Figure 2.8E-F). A predictable ~525 bp excision was present for cells co-transduced at
MOI 1, supporting the reduction in RT activity at this MOI. Shorter amplicons were
observed with MOI 0.1 treatment, however evidence of editing disappeared in stimulated
conditions. Paired with RT-activity results (Figure 2.3D), it is likely that transduction at a
low MOI proves subtherapeutic as few cells bear the CRISPR-induced indel. Conversely,
we cannot exclude the possibility that the efficacy observed at MOI 10 in the absence of
excision bands results from cytopathicity encountered with high levels of lentiviral
treatment. These results cumulatively support the utility of lentiviral delivery of TatDE
CRISPR-Cas9 in eliminating latent proviral HIV-1.
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Figure 2.6

Figure 2.6. TatDE CRISPR Co-transfection Abolishes Latent HIV-1 in Infected
ACH2 T cells.
(A) ACH2 T cells containing 1 copy of integrated HIV-1 proviral DNA were transfected
with 120 ng of CRISPR-Cas9 encoding lentiviral plasmids then stimulated and harvested
according to the diagram above. (B) Supernatants were measured by RT activity assay 72
hours post stimulation. (C) The fold stimulation in (B) was determined as the ratio of RT
activity in the presence:absence of TNFα. (D) DNA was PCR amplified to survey for
shortened amplicons resulting from CRISPR-Cas9 mediated excision of intervening DNA.
Bands were gel extracted and subjected to ICE to determine indel frequency. (E-F)
Excision bands from TatD + TatE co-transfection in the presence of TNFα were Sanger
sequenced to confirm editing in the TatD (E) and TatE (F) loci. Data in (B-C) depict mean
± SEM from three independent experiments each containing biological triplicates.
Significance assessed by two- (B) or one-way (C) ANOVA.
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Figure 2.7

Figure 2.7. TatDE CRISPR Co-transfection Reduces HIV-1 in Latently Infected U1
Promonocytes.
(A) U1 promonocytes containing 1-2 copies of integrated HIV-1 proviral DNA were
transfected with 120 ng of CRISPR-Cas9 encoding lentiviral plasmids then stimulated and
harvested according to the diagram above. (B) Supernatants were measured by RT activity
assay 72 hours post stimulation. (C) The fold stimulation in (B) was determined as the ratio
of RT activity in the presence:absence of phorbol 12-myristate 13-acetate (PMA). (D)
Nested PCR was performed to survey for shortened amplicons resulting from CRISPRCas9 mediated excision of intervening DNA. Bands were gel extracted and subjected to
ICE to determine indel frequency. (E) Excision bands from TatD + TatE co-transfection in
the presence of PMA were Sanger sequenced to confirm editing in the TatD locus. Data in
(B-C) depict mean ± SEM from two independent experiments each containing biological
triplicates. Significance assessed by two-way ANOVA.
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Figure 2.8

Figure 2.8. Lentiviral TatD + TatE CRISPR co-transduction inactivates latent HIV-1.
ACH2 CD4+ T cells bearing 1 copy of HIV-1 proviral DNA were transduced with
lentivirus bearing spCas9-gRNA transgene at multiplicities of infection (MOI) 10, 1, or 0.1.
After 72 hours, cells were stimulated with TNFα (15 ng/mL) for 72 additional hours. (A)
spCas9 expression as measured by RT-qPCR. (B-D) RT-activity assay from culture
supernatants. (E) Nested PCR for proviral DNA excision wherein unedited amplicons are
2986 bp and CRISPR editing is expected at approximately 525 bp, depending on insertional

/ deletion mutagenesis. White arrow indicates expected molecular size in presence of
TatDE excision. Significance assed by two-way ANOVA.
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2.3.e Exonic disruption of the tatE locus attenuates HIV-1 replication
As a potential mechanism to explain TatE’s high antiretroviral activity despite low
sequence conservation, we investigated how disruption of different numbers of viral exons
affects HIV-1 replicative fitness. ICE analysis in our gRNA transfection screen revealed
3% of TatD edits to be 2-4 base pair insertions (Figure 2.9A). With TatE transfection, a
12-nucleotide deletion was detected (Figure 2.9A). A T cell tropic GFP-reporter strain,
HIV-1NL4-3-Δnef-eGFP, was selected as the parent clone for mutagenesis enabling the detection
of viral cell to cell spread as evaluated by flow cytometry. Three HIV-1 non-frameshift
point mutants were created to parallel CRISPR mutation profiles, in which two- (ΔTatD),
three- (ΔTatE), or five (ΔTatDE) exons were augmented (Figure 2.9B). After HIV-1NL4-3Δtat

molecular clones were detected to be p24 positive by ELISA and viral RNA (vRNA)

transcript positive by RT-qPCR (data not shown), resulting virions were imaged by
transmission electron microscopy (TEM; Figure 2.9C). The size of the HIV-1 tat mutants
ranged from 110.6-150.5 nm in diameter, closely approximating that of wildtype HIV-1
measured at 125.4 nm. Likewise, the HIV-1 tat mutants’ nearly spherical appearance and
inner conical capsid matched the morphology of wildtype control virus. Next, CD4+ T
lymphocytes were infected at a MOI of 0.1. At 10 days following HIV-1 infection,
significant differences in RT activity were detected in culture supernatants (Figure 2.9D).
HIV-1NL4-3-ΔtatD displayed nearly equivalent levels of viral replication as wildtype virus,
while mutants bearing ≥ 3 disrupted exons were significantly lower in RT activity
compared to unmutated control. As CD4+ T cell proliferation rates differed after 10 days
due to HIV-1 induced cytopathicity, the percent of cultured HIV-1 infected cells was
measured by flow cytometry during a 28-day time course (Figure 2.9E). Whereas HIV-
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1NL4-3-ΔtatD proliferation approximated that of control HIV-1, HIV-1NL4-3-ΔtatE and HIV-1NL43-ΔtatDE

remained at or around baseline for four weeks. These data suggest that the locus

targeted by TatE gRNA is critical for maximal CRISPR activity. Yet its inclusion with
TatH gRNA in our transfection screen (Figure 2.3A) did not result in complete knockdown
of RT activity. In aggregate, we conclude that the high efficacy of TatDE CRISPR-Cas9
therapy against numerous HIV-1 strains results from disrupting five viral exons
simultaneously.
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Figure 2.9

Figure 2.9. Exonic Disruption compromises HIV-1 replicative fitness.
(A) Insertion / deletion profiles among the most-efficacious single gRNA from a cotransfection screen was assessed by ICE v2.0 (Synthego) algorithm. Highest frequency
insertions or deletions were selected for subsequent non-frameshift site-directed
mutagenesis of HIV-1NL4-3-Δnef-eGFP encoding plasmid. (B) HIV-1NL4-3-Δnef-eGFP was mutated
in tat or tat/rev loci to match the most frequent indel patterns achieved in single gRNA
CRISPR plasmid screening. (C) Transmission electron micrographs of single- or dual-tat
mutants. Spherical diameter measurements were taken at the time of imaging (inset). (DE) CEMss CD4+ T cell lines were challenged at MOI 0.1 with HIV-1NL4-3-Δtat-Δnef-eGFP and
assayed at designated time points for RT activity (D) or flow cytometry (E).
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2.4. DISCUSSION

Over 79,000 unique human- or simian immunodeficiency virus (HIV/SIV) sequences
spanning eleven global subtypes have been identified

148

. The presence of a 6% mutation

rate even among elite controllers highlights the presence of a multitude of intrapatient HIV154

1 quasispecies

. These considerations led us to design CRISPR-Cas9 guide RNAs

(gRNAs) against conserved and multi-exon regions of a consensus HIV-1 sequence,
termed “mosaic gRNAs”, to facilitate viral elimination. Herein, we introduce exonic
disruption as a guiding for CRISPR therapeutics as a required link to control residual viral
infection
Finding operational utility for CRISPR as an HIV-1 treatment is contingent on
identifying and eliminating portions of a heterogeneous viral genome. A solution is found
building on prior works demonstrating superior antiviral efficacies of LTR- or tat/rev
directed gRNAs against selective HIV-1 strains 51-54,61,62. However, despite these in silico
predictions

65,94

, interrogations of conserved gRNAs targeting the HIV promoter, LTR,

have failed to experimentally determine the CRISPR’s potential against clinical HIV-1
variants. We reasoned that inactivating transcriptional regulators tat/rev would achieve a
solution by yielding similar levels of viral repression for multiple HIV-1 strains. Indeed,
the data now provided in this report establish an association between tat/rev target DNA
conservation and CRISPR-Cas9 efficacy across multiple HIV-1 transmitted founder strains
(Figure 2B). The impact of this finding is twofold. First, it validates our mosaic gRNA
approach as a tenable means of using CRISPR to inactivate genetically heterogenous viral
targets. Three of our four most efficacious gRNAs, TatD, TatH, and TatG, designed against
exon 1 of tat (and rev), prompted 42-48% knockdown in HIV-1 RT activity. The result
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accords with a reported 40% reduction in HIV-1 protein levels using a tat/rev-targeting
Cas12a crRNA 54. Second, the correlation reveals that conserved tat/rev-directed gRNAs
outperform LTR-based reference controls. Given that these were selected for their potential
to recognize divergent HIV-1 quasispecies in patients
infected hosts

68

and facilitate elimination from

155

, their inferiority relative to our top gRNA candidates- TatD and TatE-

represents an advance in improving CRISPR therapy as a strategy for HIV-1 elimination.
A second limitation by this approach is in providing an explanation for the high
efficacies of some tat-targeting gRNAs. Variables would include on-target cleavage
efficiency, target DNA conservation, excision length, and numbers of disrupted exons
during CRISPR-Cas9 treatment. Similar to the efficacy seen with another tat/rev/gp41targeting gRNA

62

, TatE CRISPR treatment reduced RT activity by an average of 76%

despite bearing complete complementarity to only 15% of known HIV-1 sequences. To
explain these findings, we propose exonic disruption as a critical component for CRISPR
inactivation of HIV-1 proviral DNA. Non-frameshift site-directed mutagenesis of 3 or
more exons at the TatE locus, but not 2 exons at TatD, significantly suppressed viral
replication. In our gRNA co-transfection screen, the most broadly active CRISPR
treatments included tat/rev/gp41-directed TatE. One implication that follows is that
transmission of TatE-directed CRISPR may help overcome low potency

100

and viral

escape 64,101 otherwise associated with single gRNA treatment of HIV-1. These results also
suggest that cleavage at other multiexon locations along the HIV-1 genome, such as
gag/pol and nef/LTR, or at tat/rev/gp41 by other Cas nucleases

54,156

may afford broader

antiviral coverage. Thus, exonic disruption paired with target DNA conservation appear
integral in generating effective HIV-1 CRISPR therapeutics.
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Delivery of HIV-1 specific CRISPR payloads remains one final parameter yet to
be optimized prior to human administration. Current ex vivo approaches ablate the HIV-1
co-receptor, CCR5, with CRISPR-transducing lentiviruses 71,96. However, the 5% editing
efficiency in transduced human hematopoietic stem cells failed to render viral suppression
on antiretroviral drug withdrawal18. In contrast, systemic administration of CRISPR
directly targeting HIV-1 LTR using both lentivirus and adeno-associated virus 9 has
enabled at least partial cures in humanized mice

113,145

. These findings informed our

strategy to deploy TatDE CRISPR via a highly efficient viral vector. With lentiviral
transduction at MOI 1, TatDE CRISPR transgene was detected at an average of 33.2
spCas9 RNA copies per AHC2 T cell with a 94% reduction in RT activity and clear viral
excision (Figure 4). In contrast, a single broad spectrum CRISPR-Cas9 targeting LTR
transduced at this same level still allowed viral rebound in ~20% latently infected JLat cells
94

. Other studies have achieved >90% reduction in HIV-1 reactivation and prevention of

viral escape when CRISPR-Cas9 was lentiviral transduced in T cells at MOI 10-15 55,61,151.
These differences highlight the likelihood that TatDE CRISPR-Cas9 maintains greater
potency against HIV-1 than other CRISPR-Cas9 therapies. We also carried out our in vitro
experiments in the absence of puromycin selection to recapitulate the heterogeneity in
CRISPR transduction levels across a cellular population. This marks a point of divergence
from other CRISPR works that measured longitudinal anti-HIV efficacy in cells transduced
with CRISPR- and puromycin-encoding lentivirus 54,151.
A possible critique of our vector choice is that patients will likely already be
receiving combination antiretroviral drugs that inhibit lentivirus’ ability to transduce
CRISPR. Nonetheless, latently infected JLat cells, uninfected- and HIV-1-positive patient
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blood mononuclear cells have been treated successfully by lentivirus transduction in the
presence of antiretroviral drugs

55,155

. This sets a stage for future optimization of dosage

and ART timing to enable CRISPR delivery by lentivirus in HIV-1 infected patients. Phase
I clinical trials evaluating the safety of lentiviral-transduced CRISPR-Cas9 are ongoing for
B-cell acute lymphoblastic leukemia (B-ALL; NCT04557436) and HIV-1 patients in the
context of hematological malignancies (NCT03164135). Thus, our ability to deactivate
HIV-1 with lentiviral vectors may prove essential in avoiding adverse events with TatDE
CRISPR therapy.
Selectivity of the CRISPR-Cas system for HIV-1 proviral DNA is a key factor in
assessing our treatment’s therapeutic window. No off-target edits were observed with
TatDE treatment in the 10 loci surveyed by a Sanger sequencing-based algorithm. By
contrast, Inference of CRISPR Edits (ICE) data demonstrate a mean 44% editing efficiency
of proviral DNA template with TatDE CRISPR. This led to detectable excision of ~2.5 kb
of viral DNA and to nearly complete abolition of viral release. These findings are aligned
with reports that ~10% and 39-63% editing efficiencies from multiplex endonuclease
treatments resulted in more than 90% knockdown in herpes simplex virus and HIV-1,
respectively

151,157

. Dysregulation of positive feedback loops, as in the case of tat/rev-

directed CRISPR-Cas9, and the formation of dominant negative proteins encoded after
gene editing may explain the disproportionately high efficacy in each of these cases. The
HIV-1 proviral genomes isolated from elite controllers display large deletions of env
sequences flanked by tat/rev amongst other regulatory genes

158

. It is postulated that

defective virus in elite controllers primes the host immune system to clear cells bearing
replication-competent HIV-1 proviral DNA

158

. Therefore, we posit that TatDE CRISPR
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therapy may similarly compromise latent HIV-1 sequences thereby inducing immunemediated clearance in vivo.
Planned studies will serve to address future needs in translating this strategy for
human use. While our transfection screen identified broad efficacy of TatDE dual gRNAs
against 7 HIV-1 clade B molecular clones, TatDE’s multistrain potential will be further
validated against additional strains and clades for antiviral activity. We will

also

interrogate the lack off-target editing within the human genome by employing CIRCLEseq 159,160, Guide-seq 94,161 and whole genome sequencing 155 to our TatDE CRISPR-treated
samples. Finally, we plan to further characterize TatDE’s mechanism of action in terms of
its ability to downregulate full-length viral transcripts due to tat, diminish rev-associated
nuclear export, and impede gp41-mediated viral entry. These additional studies should
clarify the value in expanding in our conserved, multi-exon targeting CRISPR library to
other Cas endonucleases.
To conclude, the combination of “diverse” strain-inactivating TatD and “tri-exon”directed TatE gRNAs prompted maximal suppression of HIV-1 replication by CRISPRCas9. Further refinement of these methodologies may advance the utility of gene therapy
in eliminating latent viral infection from infected hosts across the globe.
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2.5. METHODS

2.5.a Experimental Models

Escherichia coli (STBL3, Stellar)
E. coli (STBL3, Stellar) cells used for transformation of stock or cloned plasmids were
streak plated on selective antibiotic-containing (ampicillin, 100 µg/mL OR kanamycin, 50
µg/mL) Luria Bertani (LB)-agar plates and incubated 16 hours at 37oC. Single clones were
then inoculated in LB broth containing appropriate selective antibiotic and cultured for 16
hours at 32oC with orbital shaking at 185 revolutions per minute (rpm). Selected clones
were stored in 50% glycerol / water at -80oC.

Human cell culture
HEK293FT cells were grown in DMEM containing 10% v/v fetal bovine serum (FBS),
100 units / mL penicillin and streptomycin (PenStrep), 0.5 mg / mL Geneticin®, 1% v/v
MEM non-essential amino acids (MEM NEAA), and 1 mM sodium pyruvate. Adherent
HEK293FT were detached from culture plates using 3 mL Trypsin-EDTA (0.25%) and
passaged at 3 x 106 cells in 15 mL growth media every 3-4 days. CEMss CD4+ T cells,
HIV-1 latently infected ACH2 T cells, and HIV-1 latently infected U1 promonocytes were
cultured in RPMI containing 10% v/v FBS, 100 units / mL PenStrep, and L-glutamine.
Suspension CEMss, ACH2, and U1 cells were maintained at 0.2 - 1 x 106 cells / mL by
passaging in 15 mL growth media every 3-4 days. Cells were propagated in vented cap
75cm2 U-shaped flasks at 37oC / 5% CO2.
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Method Details
2.5.b In silico HIV-1 Sequence Conservation and guide RNA (gRNA) Design
To visualize conservation of nucleotides through the HIV-1 genome, a DNA multiple
sequence alignment for each LTR or exon according to HXB2 reference strain
(https://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html) from the Los
Alamos National Library (LANL) HIV sequence database (https://www.hiv.lanl.gov/)
using all complete sequences available through 2018. The exported FASTA files were
input to WebLogo 3 (http://weblogo.threeplusone.com/create.cgi) and the resulting plain
text data table of positional entropy was graphed in heat-map form. Consensus sequences
lacking gaps for the entire HIV-1 genome and tat using the LANL multiple sequence
alignments were generated using SnapGene® software (GSL Biotech). CRISPR gRNAs for
HIV-1 tat were designed using CHOPCHOP v3
Broad

Institute

GPP

162

(https://chopchop.cbu.uib.no) and
sgRNA

(https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design)

Designer
using

tat

consensus sequence as the specified target and human GRCh38 as the host organism. The
top 35 gRNA candidates were inspected in WebLogo to identify the 8 gRNA with highest
degrees of conservation among HIV-1 strains. Guide RNA conservation percentages for
the full 20 base pair target were also determined using SnapGene®. The specificities of tatand control-targeting gRNAs were predicted using Broad Institute GPP sgRNA Designer
and CRISPR-OFF webserver v1.1 (https://rth.dk/resources/crispr/crisproff/). Putative offtarget loci for top gRNA candidates were selected from top-ranked candidates in CRISPROFF and Cas-OFFinder (http://www.rgenome.net/cas-offinder/) tools.
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2.5.c Cloning
CRISPR U6::gRNA-U6::gRNA-CBh::spCas9 “all in one” px333 (Addgene plasmid #
64073) and pLentiCRISPR-RFP657 (Addgene plasmid # 75162) were restriction enzyme
digested using BsaI, BbsI, or Esp3I as appropriate. Digested vectors were extracted from
1% agarose / TAE using GeneJET gel extraction kit (Thermo Scientific). Guide RNA
recognition domain inserts flanked with cacc or caaa sticky ends were generated by primer
annealing in 10 mM Tris pH 8.0, 50 mM NaCl, 1 mM EDTA using thermal cycling
touchdown (95oC – 25oC, Δ1oC, 45 seconds per stage). Vector and insert were adhered
using T4 ligase reacted for 16 hours at 4oC, followed by heat inactivation at 65oC for 15
minutes. pHIV-1NL4-3-Δtat mutants were generated by site-directed mutagenesis of pHIV1NL4-3-Δnef-eGFP (a gift from Dr. Won Bin Young- U. of Pittsburgh, Pittsburgh, PA; and Dr.
Kamel Khalili, Temple University, PA) using In-Fusion cloning (Takara) according to
manufacturer’s specifications and recommended primer pairings. Primers used for
insertional and mutagenesis cloning are summarized in Appendix II. CRISPR plasmid
constructs

and

HIV-1

molecular

clones

pHIV-1NL4-3-Δnef-eGFP,

pCH040.c/2625,

pCH106.c/2633, pTHRO.c/2626, pREJA.c/2864, pTRJO.c/2851 were transformed into
STBL3 E. coli. Mutant pHIV-1NL4-3-Δtat were transformed in Stellar Competent E. coli.
Plasmids were extracted via miniprep and Sanger sequenced to confirm cloning success or
via maxiprep for subsequent transfection.
2.5.d Transfection
HEK293FT cells were seeded 24 hours prior to transfection in DMEM growth media
lacking geneticin at 5 x 105 cells / well in 12-well plates (px333-pHIV-1 co-transfection
screen) or 6 x 106 cells / 10-cm dish (stock HIV-1 generation). Four hours prior to
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transfection, media was exchanged to OptiMEM containing 250 µM chloroquine
diphosphate (1 mL per well or 8 mL per 10-cm dish). Polyethyleneimine (PEI; linear MW
25,000 Da) stock (1 mg/mL) was diluted in OptiMEM to account for a 3:1 w/w PEI:DNA
ratio. For gRNA co-transfection screening, 1.5 µg px333 plus 1.5 µg pHIV-1 were diluted
in 150 uL OptiMEM, which was then further diluted with 150 uL OptiMEM / PEI. Viral
stock transfections were similarly prepared using 10 µg pHIV-1 diluted in 1.5 mL
OptiMEM, which was then further diluted with 1.5 mL OptiMEM / PEI. DNA / PEI
mixtures were incubated for 15 minutes at 25oC prior to addition to cell cultures (100 uL /
well in biological triplicates = 1 µg DNA / well; 3 mL / 10 cm dish = 10 µg DNA / 10 cm
dish). Sixteen hours post-transfection, DMEM growth media lacking geneticin was
replaced and cultured for 72 hours until experimental or lentivirus harvesting. ACH2 and
U1 cells were seeded in 90 µL at 5 x 104 cells / well in round-bottom 96-well plates 24
hours prior to transfection with pLentiCRISPR-RFP657. 1.08 µg pLenti-CRISPR-RFP657
plasmid was diluted in 81 uL OptiMEM, then supplemented with 3.24 µL TransIT®-Jurkat
transfection reagent. After 20 minutes incubation at 25oC, 10 uL of the transfection
mixtures were added per well in biological replicates (n = 8) and cultured for 72 hours
followed by chemical stimulation to assay viral outgrowth.
2.5.e Lentivirus Production, Titering, and Transduction
Supernatant from pHIV-1 transfected HEK293FT was collected 72 hours post-media
exchange, centrifuged 650 RCF for 10 minutes to remove cellular debris and filtered across
0.45 µm PVDF membranes to exclude large exosomes and proteins. HIV-1 was
concentrated by layering 10 mL of the filtered supernatant on 2.5 mL 10% w/v sucrose in
50 mM Tris-HCl, 100 mM NaCl, 0.5 mM EDTA, followed by ultracentrifugation at
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112,000 RCF for 3.5 hours at 4oC. Resulting pellets were resuspended in 250 uL PBS,
aliquoted at 50 uL per tube, and stored -80oC. HIV-1 viral stocks were titered using the
Lenti-XTM qRT-PCR Titration Kit according to the manufacturer’s protocol. Preparation
of third generation CRISPR-transducing lentivirus using our cloned pLentiCRISPRRFP657 was commercially outsourced the University of Iowa Viral Vector Core Facility
(https://medicine.uiowa.edu/vectorcore/), and titered using digital droplet PCR. U1 or
ACH2 cells were seeded at 3 x 104 cells / well in round-bottom 96-well plates 24 hours
prior to transduction, in the absence or presence of IL-7 (5 ng / mL) mitogen, respectively.
Virus was diluted in serum-free RPMI containing 8 µg / mL polybrene. Multiplicities of
infection (MOIs) were calculated as viral RNA copies / cell for HIV-1 infection and
transducing units / cell for CRISPR-transduction. Wells were infected or transduced using
50 µL diluted virus / well and spin-inoculated at 2400 RCF for 2 hours at 25oC. Microtiter
plates were then incubated for 4 hours at 37oC / 5% CO2 and supplemented with 100 µL
growth media. Sixteen hours thereafter, cells were washed 3x in PBS and cultured in 100
µL growth media, which was exchanged every 48 hours until experimental termination.
2.5.f Viral Outgrowth Assays
Transfected or transduced latently infected ACH2 and U1 cells media were stimulated 15
ng / mL TNFα (ACH2 cells) or 20 ng / mL phorbol 12-myristate 13-acetate (PMA; U1
cells) diluted in growth media in biological quadruplicate. Biological quadruplicates
cultured in growth media alone served as unstimulated controls. Cells were further
incubated for 72 hours until terminal harvest.
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2.5.g Nucleic Acid Isolation
Biological replicates were pooled and fractioned for DNA and RNA extraction. DNA was
extracted using NucleoSpin Tissue XS Micro kit (Machery-Nagel) according to the
manufacturer’s protocol. TRIzol (Invitrogen) RNA extraction was performed beginning
with addition of 600 µL TRIzol to cell pellets followed by mechanical lysis at 30 Hz for
10 minutes using a TissueLyser II instrument (Qiagen). Subsequent steps were performed
according

to

the

TRIzol

User

Guide

(https://assets.thermofisher.com/TFS-

Assets/LSG/manuals/trizol_reagent.pdf) with volumes scaled proportionately to account
for the initial 600 µLTRIzol.
2.5.h Polymerase Chain Reaction (PCR)
CRISPR-mediated excision of proviral DNA was determined by PCR using 150 ng
template DNA, 12.5 µL PrimeTime Gene Expression Master Mix (IDT), 1 µL of each 10
µM forward and reverse primers, and volume adjusted to 25 uL with water. Conventional
PCR was performed using thermal cycling under the following conditions: 95oC for 3
minutes; 35 cycles of 95oC for 5 seconds, 61.4oC for 30 seconds, 72oC for 30 seconds; and
72oC for 5 minutes. Nested PCR was performed by subjecting DNA from latently infected
ACH2 or U1 cells to 15 rounds of PCR as described above. Contents were then diluted
1:10 in water and 2 µL thereof served as template to 30 additional rounds of PCR using
nested primers 300b and 301b according to identical thermal cycling conditions. Off-target
PCRs were performed using 150 ng template DNA extracted from HEK293FT transfected
cells, 12.5 µL AmpliTaq Gold 360 master mix, 2.5 µL GC enhancer, and volume adjusted
to 25 µL with water. Thermal cycler conditions were as follows: 95oC for 10 minutes; 35
cycles at 95oC for 30 seconds, 52-60oC (depending on primer Tm) for 30 seconds, and
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72oC for 30 seconds; and 72oC for 7 minutes. Sequences of PCR primers are provided in
Appendix III. PCR contents were run in 1% agarose / TAE gels by electrophoresis at 75V
for 35 minutes. Gel-extracted PCR amplicons and total PCR contents were Sanger
sequenced and subjected to Synthego Inference of CRISPR Edits (ICE) Analysis v2.0
(https://ice.synthego.com/#/; accessed March – November 2020).
2.5.i RT-qPCR
For quantitative reverse transcriptase PCR (RT-qPCR), 10 ng RNA was first digested with
DNase I (Zymo Research). Reverse transcriptase reactions were carried out (42oC for 30
minutes, 95oC for 2 minutes) using Verso cDNA Synthesis Kit (Thermo Scientific) in a
volume of 10 µL using 1 µL of DNase I (Zymo Research) treated RNA and random
hexamers. RT-qPCR was subsequently performed to measure gapdh or spCas9 expression
using standard curve-based absolute quantitation. A standard curve (105-1 copy) was
generated for gapdh using DNA collected from untreated ACH2 cells using a conversion
of 1 diploid genome = 6.6 picograms. An spCas9 standard curve (109-103 copies) was made
using pLenti-CRISPR-RFP657 using the plasmid molecular weight of 7.22 x 106 Da to
calculate that 109 copies equal 12.01 ng. Ten microliter spCas9 RT-qPCR reactions were
prepared using 1 µL cDNA template, 5 µL PrimeTime Gene Expression Master Mix (IDT),
0.5 µL of each 10 µM forward and reverse primers, and 0.2 µL 10 µM TaqMan probe. RTqPCR for reference gene were similarly carried out using 0.5 µL Human GAPDH
Endogenous Control (Applied Biosystems). All RT-qPCR reactions were performed in
technical triplicates under the following thermal cycling conditions: 95oC for 3 minutes,
60 cycles of 95oC for 15 seconds followed by 60oC for 1 minute. Primers and probe
sequences are provided in Table S4.
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2.5.j Reverse Transcriptase (RT) Activity Assay
In 96-well round-bottom plates, 10 µL of culture supernatants from biological replicates (n
≥ 3) were added to 10 µL RT solution A (100 mM Tris-HCl pH 7.9, 300 mM KCl, 10 mM
DTT, 0.1% NP-40) then incubated for 15 minutes at 37oC / 5% CO2. Twenty-five
microliters of RT solution B (50 mM Tris-HCl pH 7.9, 150 mM KCl, 5 mM DTT, 15 mM
MgCl2, 0.05% NP-40, 0.250 U/mL oligo dt pd(T)12-18) containing freshly supplemented 10
µCi / mL 3H-TTP (4 µL / mL; 3H-deoxythimidine 5’-triphosphate, tetrasodium salt,
(methyl-3H)) were then added to each reaction well and incubated 20 hours at 37oC / 5%
CO2. Fifteen minutes prior to harvesting, 50 µL of ice cold 10% trichloroacetic acid (TCA)
was added. Contents were then vacuum filtered across 96-well MicroHarvest Plates
(Millipore). Plates were subsequently washed 3x with each 100% TCA and 100% ethanol
and dried for 5 minutes at 67oC. Twenty-five microliters of Microscint-20 (Perkin Elmer)
were pipetted to each well. Plates were read via TopCount Scintillation counter (Perkin
Elmer). Radioactive counts per minute (CPM), proportionate to the amount of virus
contained in sample supernatant, were normalized to trypan blue-based cell counts taken
at the time of harvest.
2.5.k Flow Cytometry
CEMss CD4+ T cells infected with GFP-reporting HIV-1NL4-3-Δtat-Δnef-eGFP were washed
once with PBS and fixed in 2% paraformaldehyde (PFA). GFP expression was measured
in fixed cells using an Attune NXT Flow Cytometer (Thermo Fisher) and reported as % of
gated single-cell population.
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2.5.l Statistical Analyses
Experiments were run in biological replicates (n = 3 or 4) in at least two separate trials, as
indicated in figure legends. RT activity assays and RT-qPCR were further performed with
technical triplicates. Data are presented as means ± standard error of the mean (SEM).
Pearson correlation between mean RT activity reductions and percent gRNA conservation
was performed using two-tailed p-value determination. Statistical differences between
unstimulated vs stimulated RT activity values and stimulated control vs stimulated
treatment RT activity values were calculated with two-way ANOVA by Sidak correction
for multiple comparisons. One-way ANOVA with Dunnett correction for multiple
comparisons was employed to assess for statistical differences between the stimulation
indices of control- and tat-targeted treatments. All statistical calculations set type I error
cutoff α = 0.05 and were performed using GraphPad Prism v7.0a for Mac OS X (GraphPad
Software, San Diego, California USA, www.graphpad.com).
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CHAPTER 3
CRISPR-Cas9 Delivery Modalities for HIV-1 Elimination

3.1. ABSTRACT

With numerous strategies to directly target the HIV-1 genome via CRISPR-Cas9,
a unifying question endures as to how best to deliver this gene editing therapy. Viral vectors
remain a classically preferred route for preclinical testing given their reliability and
simplicity in design. Adeno-associated virus 9 (AAV9) and lentivirus are two such methods
that have been demonstrated in vivo to eliminate all traces of HIV-1 from humanized mice.
Yet, alternative modes of CRISPR delivery may offer reduced risk of toxicity, greater
scalability, and flexibility for customization. We present data that negates the obvious
utilization of AAV9 and HIV-1 virus-like particles (VLPs) for HIV-1 elimination from
human CD4+ T cells and macrophages. Preliminary data in support of a nanoparticle-based
platform for TatDE CRISPR therapy is introduced, with an eye towards its future
development.
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3.2. INTRODUCTION

Delivery of CRISPR-Cas9 for elimination of HIV-1 remains a challenge. Although
evidence of its feasibility in humanized mice has been demonstrated with both adenoassociated virus 9 (AAV9)155 and lentivirus113, questions regarding the therapy’s
translatability to human patients endure. Identifying limitations to the AAV vector will
therefore aid in optimizing alternative strategies by which to clear all traces of HIV-1
proviral DNA.
While AAV-mediated gene therapy has been extensively used in pre-clinical and
clinical studies, it possesses several limitations. AAV9’s transduction efficiency in primary
CD4+ cells remains at < 5%115, which may explain the usage of 1012 viral genomes /
humanized mouse to achieve HIV-1 elimination. AAV9 doses three orders of magnitude
higher would likely be required to adequately reach all latently infected cells for humans116.
AAV also transduce large numbers of cells that are not targets for HIV-1 by AAV-tethering
to sialic acids163-167 or platelet-derived growth factor receptor168 as ligands. Off-target
effects in the brain167 and liver169 have thus been associated with AAV’s lack of selectively.
In vitro demonstrations of AAV’s antiviral efficacy for HIV-1 is limited to transgenic rat
cell lines112,170 and latently infected human neurons170, but are notably absent in human
leukocytes. Lastly, AAV accommodates only ~5 kb oligonucleotide payloads, limiting the
breadth of CRISPR gRNAs that can be encapsulated and required to excise broad ranges
of integrated HIV-1 genomic DNAs.

70

A prime vector candidate to overcome these challenges includes virus-like particles
(VLPs). VLPs are self-assembling pseudoviral structures lacking infectious capabilities.
To date, VLPs are being utilized to vaccinate against human papillomavirus (phase III
clinical trial)171 and hepatitis B172. Vesicular stomatitis virus enveloped (VSV-G) VLPs
have already been reported to carry pro-apoptotic anti-cancer TRAIL to tumors173 and
CRISPR-Cas9 ribonucleoprotein to embryos174 by generating viral-fusion proteins.
Accordingly, HIV-1 VLPs may similarly prove suitable in directing CRISPR selectively
to CD4+ T cells and mononuclear phagocytes.
Lastly, CRISPR-Cas9 nanoparticles have been developed in recent years as nonviral vehicles for the gene editing technology. This modality has been developed for
CRISPR mRNA128 and ribonucleoprotein (RNP)127. Advantages of this approach are that
the nanoparticle coatings can be tuned for organ-specific or cell-type specific delivery128.
Proof-of-concept has been achieved using CRISPR nanoparticles in engineering particular
genotypes in mouse embryos123 and correcting human genetic mutations responsible for
Duchenne’s muscular dystrophy and hypercholesterolemia in live murine models127,175.
Given the scalability and flexibility in nanoparticle production, utilizing CRISPR-Cas9
nanoparticles for HIV-1 elimination may prove beneficial.
Herein, three vectors- AAV9, VLPs, and nanoparticles- are experimentally
evaluated for their compatibility with CRISPR-based inactivation of HIV-1. Data negating
the utility of AAV9 and VLPs in CD4+ leukocytes are presented. In contrast, preliminary
findings of proviral excision using CRISPR nanoparticles suggest the need for further
development of this strategy.
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3.3. RESULTS

3.3.a Limitations in rAAV9/CRISPR-Cas9 Delivery to HIV-Infectible Leukocytes
To validate recombinant adeno-associated virus 9 (rAAV9) as a suitable CRISPRtransducing vector for HIV-1 elimination, human cell culture experiments were performed.
The efficacy of rAAV9/CRISPR-Cas9 delivering LTR-1/GagD excision gRNAs was first
assessed in monocyte-derived macrophages (MDMs). It is postulated that induction of viral
latency, meaning blockade of all HIV-1 transcription, is necessary for CRISPR-Cas9 to
eliminate the virus. Failure to achieve such leaves open at least the theoretical possibility
for viral proteins to assemble and complete the HIV-1 lifecycle. To most closely simulate
productive infection in vivo, MDM were infected with HIV-1, then treated with induction
therapy using ART or LASER ART cocktails to maximally repress viral replication
(Figure 3.1A). Following a 12-day washout period to accentuate differences in ART or
long-acting slow-effective release (LASER) ART, LTR-1/GagD CRISPR was
administered by rAAV9 transduction (MOI 100,000). Independent cell vitality assays
demonstrate that none of the experimental treatments were cytotoxic to MDM (Figure
3.1C). Antiretroviral therapy and LASER ART lowered viral replication by 94% and 98%,
respectively, prior to rAAV9/CRISPR-Cas9 transduction (Figure 3.1B). CRISPR
monotherapy elevated viral replication, while administration of CRISPR adjunctively to
ART failed to slow the viral rebound 17-21 days post-infection (Figure 3.1B). Terminal
RT-qPCR revealed that although LASER ART treatment significantly lowered viral
transcripts from untreated controls, rAAV9/CRISPR-Cas9 did not further reduce viral
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replication as would be expected with gene editing of proviral DNA (Figure 3.1D). As no
efficacy was observed with CRISPR treatment in macrophages, further analysis of the
proviral DNA in these samples was bypassed.
The utility of rAAV9/CRISPR-Cas9 was next studied in CD4+ T cells, the main
target of HIV-1 infection. CEM CD4+ T cells were first infected with lymphotropic strain
HIV-1NL4-3 (MOI 0.01). As productive infection in lymphocytes variably depends on
mitotic and immune activation states176, ART or LASER ART initiation was delayed by 2day intervals to ensure integration of proviral DNA as a substrate for CRISPR excision
(Figure 3.2A). Thereafter, LTR-1/GagD CRISPR-Cas9 was transduced by rAAV9 (MOI
500,000), followed by 13 days of ART or LASER ART therapy (Figure 3.2A) to prevent
viral rebound as observed in macrophage cultures (Figure 3.1B). DNA-based analyses
were performed at experimental terminus to investigate the possibility of CRISPR-based
excision. Droplet digital PCR (ddPCR) demonstrates lower copy numbers of HIV-1
proviral DNA with LASER ART treatment (0.1 – 7 gag copies per cell) than with ART
(300 – 900 copies gag copies per cell) (Figure 3.2B). CRISPR co-treatment modestly
reduced the amount of proviral DNA when LASER ART was initiated 1-day post-infection
(Figure 3.1B). To determine whether the reduction was due to proviral DNA excision,
conventional PCR was performed. No excision bands, which mark the dropout of 979
proviral nucleotides between gRNA cut sites, were observed in any treatment group
(Figure 3.1C). Moreover, initiation of LASER ART one day post-infection halted the
establishment of infection altogether as exhibited by the lack of even full-length amplicons
(Figure 3.1C). To determine whether rAAV9 transduced the CRISPR therapy, ddPCR was
performed on sample cDNA. Results reveal 2 – 20 copies of saCas9 cDNA transcripts per
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cell in all CRISPR treated groups, which all fell above the assay detection limit of 0.2
copies / cell (data not shown). These data cumulatively suggest that rAAV9 fails to
effectively transduce CRISPR at therapeutic levels in CEM CD4+ T cells.
Figure 3.1

Figure 3.1. rAAV9/CRISPR-Cas9 does not boost antiviral efficacy in monocytederived macrophages (MDM).
(A) MDM were infected with HIV-1, then treated for 1 day with 4 drug ART (dolutegravir
(DTG) 26.4 nM; rilpivirine (RPV) 8.95 nM; lamivudine (3TC) 75 µM; abacavir (ABC) 29
µM) or corresponding LASER ART cocktails (NMDTG, NRPV, NM3TC, AND NMABC
at equivalent concentrations) at 5x reported EC90 values. After a 12-day drug washout
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period, macrophages were transduced with LTR-1/GagD CRISPR-Cas9 (CC9) treatments
via recombinant adeno-associated virus 9 (rAVV9) at 100,000 genome copies (gc) per cell.
DNA was collected 21 days post-infection and 7 days after CRISPR treatment to survey
for antiviral efficacy. (B) Viral replication was measured in culture supernatants
throughout the time course via RT activity assay. (C) Treatments were pre-determined by
mitochondrial vitality assay (MTT) to be non-toxic compared to DMSO (0.1% v/v) vehicle
control. (D) Viral RNA was quantified by RT-qPCR on day 21 post-infection. Bars
represent means ± SEM of biological replicates (n = 4) in (B-C) and technical triplicates
(D). Significance determined by student’s t test.
Figure 3.2
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Figure 3.2. No evidence of LTR-Gag excision in HIV-infected CD4+ T cells
transduced with rAAV9/CRISPR-Cas9.
(A) CEM CD4+ T cells were infected with HIV-1NL4-3 (MOI 0.01). ART or LASER ART
was then initiated 1, 3, or 5 days post-infection at 5x reported EC90 concentrations.
Treatment groups were transduced with LTR-1/GagD CRISPR-Cas9 via rAAV9 (MOI 5
x 105 gc / cell) on day-7 post infection, and harvested 7 days thereafter. (B) Reductions in
viral DNA copies was assessed by ddPCR. (C) PCR was performed to survey for CRISPRmediated excision of ~979 bp of proviral DNA intervening 5’ LTR and gag target loci.

3.3.b HIV-1 Virus-like Particles (VLPs) for CRISPR-Cas9 Delivery
As rAAV9 lacked the ability to transduce HIV-infectible cells in vitro, we sought
to develop a more robust mode of CRISPR transmission: VLPs derived from HIV-1. We
hypothesized that pseudotyping a delivery vehicle with the HIV-1 envelope would
facilitate delivery to its natural targets- macrophages and CD4+ T cells. The envelope from
a dual tropic strain, HIV-189.6, was therefore selected for pseudotyping. To devise a
versatile loadable core functionally distinct from lentiviruses that transport transgene
cargos, three modifications were made to a packaging construct (Figure 3.3B). First,
portions of reverse transcriptase (RT) and integrase-encoding genes were deleted with a
dual-cutting enzyme, BsrGI. Second, a tethering system, termed “AviTag”, was clonally
inserted in the matrix-encoding portion of HIV-1 gag. In the presence of biotin ligase, birA,
AviTag peptide is biotinylated. In this strategy, fusion of Cas9 to a high affinity avidin
(“maxavidin”) would facilitate the active loading of CRISPR ribonucleoproteins (RNPs)
in the matrix of VLPs. Third, we genetically fused maxavidin to the capsid-encoding
portion of gag to enable delivery of biotinylated cargo. It was envisioned that in addition
to bringing CRISPR RNPs to HIV-1 infected cells, biotinylated antiretroviral prodrugs
(“bioART”) could be packaged within VLPs as well. Accordingly, co-transfection of the
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modified packaging construct along with plasmids encoding HIV-189.6env and birA would
yield HIV-1 VLPs with innate targeting abilities for CD4+ leukocytes.
Proposed modifications were tested in isolation for feasibility of constructing HIV1 VLPs, then assessed for overall for antiviral efficacy. Co-transfection of unmodified
packaging plasmid with pHIV-189.6env produced pseudovirions with appropriate 150 nm
diameters and spherical morphologies along with inner conical capsids (Figure 3.4A).
Western blot analysis demonstrated appropriate antigenicity for envelope glycoprotein 120
(gp120) and capsid (p24) (Figure 3.4B). To ensure that pseudovirions were not replication
competent, a reporter assay was performed. TZM-bl cells bear the luciferase gene under
the LTR promoter177. Infection of these cells with replication competent HIV-1
appropriately drove luciferase expression, whereas treatment with equivalent amounts of
VLP failed to do so (Figure 3.4C). Individual modifications were next made to the VLP
packaging construct. Deletion of RT with BsrGI abolished RT activity (Figure 3.4D).
Genetic fusion of AviTag to viral matrix further enabled encapsulation of UV-excitable,
streptavidin quantum dots (Figure 3.4E-F). This preliminary finding offered support for
the encapsulation of avidin-fused CRISPR ribonucleoproteins. Finally, the ability of VLPs
to carry biotinylated small molecule cargos was tested. Genetic fusion of maxavidin, a
derivative of streptavidin, to the capsid-encoding portion of gag (i.e. p24) yielded blue
VLPs when synthesized in the presence of a visibly blue biotinylated dye (Figure 3G).
CRISPR RNPs carrying LTR-1/GagD gRNAs were next loaded into VLPs constructed
with 2 (RT deletion and AviTag insertion) or 3 modifications to packaging construct.
Treatment of TZM-bl cells transfected with HIV-1 encoding plasmid and ACH2 T cells
that bear latent HIV-1 with the resulting VLPs repeatedly failed to demonstrate evidence
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of CRISPR-mediated excision (data not shown). ELISA performed on batches of VLPs
produced with these modifications showed that on average 100 – 500 ng of vector were
produced per batch, and their morphologies appeared visibly similar to HIV-1 by TEM
(data not shown). Thus, it is surmised that VLPs likely failed due to disruption of critical
viral architecture in the matrix or RT portions of the packaging plasmid, rather than due to
treatment at subtherapeutic levels. Parallel efforts to chemically synthesize biotinylated
cabotegravir as a VLP cargo likewise proved unfruitful (data not shown). To this end,
designing HIV-1 VLPs capable of delivering CRISPR therapeutics requires higher
preservation of packaging scaffold with minimal genetic modifications to improve
likelihood of therapeutic success.
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Figure 3.3
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Figure 3.3. HIV-1 VLP design.
Therapeutic-loadable VLPs are generated via co-transfection of HEK293FT producer cells
with plasmids encoding dual-tropic HIV-189.6env and modified packaging (PAX) proteins.
(A) Schematic of addition of AviTag and maxavidin sequences into p17 and p24,
respectively, as well as deletion of significant portions of reverse-transcriptase and
integrase genes. (B) Final packaging construct map with nonfunctional RT and integrase
greyed out. (C) Final VLP product schematic. p17::AviTag becomes biotinylated in the
presence of BirA ligase, enabling avidin payload binding. p24::maxavidin fusions allow
loading of biotinylated small molecules. Env: envelope; SA-QD: streptavadin quantum
dots; bioART: biotinylated antiretroviral therapy; MaxCas9: Cas9::maxavidin fusion
ribonucleoproteins carrying CRISPR gRNAs.
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Figure 3.4

Figure 3.4 HIV-1 virus-like particle (VLP) characterization.
Concentrated VLPs were characterized by (A) transmission electron microscopy for
morphology, (B) HIV-1gp120 (top) and HIV-1p24 (bottom) antigenicity by Western blot,
and (C) replication competence via TZM-bl luciferase assay. (D) RT-activity assay was
performed on VLPs synthesized using BsrGI restriction enzyme digested modified
packaging (PAX) plasmid. (E) VLPs with biotinylated HIV-1 matrix (p17::AviTag)
demonstrate streptavidin quantum dot (SA-QD) loading as observed by the UV-excitable
concentrated product. (F) The red emission of SA-QD loaded VLPs was quantified by
spectrophotometry. (G) VLPs containing biotinylated Promofluor647 synthesized with
p24::maxavidin construct demonstrate visibly colored precipitate.
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3.3.c CRISPR-Cas9 Delivery via Nanoparticles for HIV-1 Elimination
A non-viral alternative mode for CRISPR delivery in vivo is via nanoparticles. We
hypothesize that mesoporous cores, comprised of gold and / or silica, will serve as suitable
platforms for loading with CRISPR-encoding DNA and CRISPR ribonucleoproteins.
Mesoporous nanoparticle cores can be complexed with radiolabel tracers, such as indium111, that will enable real-time biodistribution studies with SPECT-CT (Figure 3.5A). Once
synthesized, the cores can be complexed with CRISPR RNPs (Figure 3.5B) or CRISPR
plasmids (Figure 3.5C). Final configurations will bear a biocompatible lipid shell
containing phosphatidylcholine (PC), Dioleoyl phosphatidylethanolamine (DOPE), and
DSPE-PEG2000. It is envisioned that the hollow microtubes within mesoporous cores will
potentiate adequate loading and timed-release of CRISPR therapeutics, while the
biocompatible lipid shell will protect the contents from degradative enzymes present in the
blood stream.
Preliminary studies were performed to survey the potential of two CRISPR
nanoparticles for HIV-1 elimination. First, plasmid-bearing mesoporous silica
nanoparticles (MSNPs) were constructed then tested. TEM micrographs reveal the silica
cores to be approximately 120 nm in diameter (Figure 3.6A). Plasmids encoding our
TatDE CRISPR system (pTatDE) were utilized. Second, CRISPR ribonucleoproteins
(RNPs) were encapsulated directly in lipid shells to spare exposing Cas9 protein to harsh
chemicals and temperatures during particle synthesis. RNPs were constructed using
synthetic gRNAs that target HIV-1 TatD and TatE loci. Following particle synthesis,
MSNPs and lipid coated RNPs were digested with DNase and RNase, respectively, to limit
the possibility of unloaded materials driving CRISPR excision. Pre-experimental gel
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electrophoresis of materials showed disappearance of plasmid control when digested with
DNase (data not shown). Additionally, plasmid and RNPs loaded in the nanoparticles were
retained in wells at the loading position, indicating the payloads were entirely encapsulated
during synthesis and therefore shielded from current that would induce migration in gel
electrophoresis (data not shown). Next, all particles were tested for ability to excise HIV1-encoding plasmid DNA in a HEK293FT transfection screen (Figure 3.6B). As expected,
unencapsulated plasmid and unencapsulated RNP produced 532 base pair excision bands.
Unloaded nanoparticle controls (lanes 5 and 9) yielded full-length 3 kb PCR amplicons.
MSNPs bearing TatDE plasmid and lipid-coated nanoparticles carrying TatDE RNPs
displayed presence of HIV-1 excision. However, enzyme digestion of the formulations
prompted the disappearance of these bands. Two possible conclusions might follow. One
explanation is that excision in these experimental groups was due to trace amounts of
unencapsulated CRISPR. Therefore, enzyme digestion of the therapeutic TatDE plasmid
or TatDE gRNAs in RNPs induced loss of excision. A second explanation could be that
the therapeutics were successfully loaded within lipid shells, however the particles degrade
under aqueous conditions. As the digestion reactions are carried out in buffered water
solutions and terminated at 65oC, it might emerge that CRISPR-mediated excision could
not occur after nanoparticles were degraded. Thus, further experimentation exploring the
stability and capacity for CRISPR loading of nanoparticles is warranted prior to
downstream applications.
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Figure 3.5

Figure 3.5. Mesoporous nanoparticle (MNP) design for CRISPR plasmid and
ribonucleoprotein theranostics.
(A) MNPs gold cores will be doped with indium-111 (111In) radiolabel for real-time
tracking and functionalized for nucleotide adherence via thiol chemistry. (B) Loading
strategy to insert TatDE CRISPR ribonucleoproteins (RNPs) payloads within gold core
MNPs (Au@MNPs), followed by the addition of a lipid shell to enhance cellular uptake.
(C) Alternate configuration to insert TatDE CRISPR-encoding plasmid (pTatDE) within
silica-gold core MNPs (SiAu@MNPs), also encapsulated within a lipid shell.
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Figure 3.6

Figure 3.6. CRISPR nanoparticle-based delivery potentiates proviral DNA excision.
(A) TEM micrograph of mesoporous silica nanoparticle (MSNP) core. (B) HEK293FT cotransfection screen of CRISPR MSNP and lipid-coated ribonucleoprotein nanoparticles for
excision of HIV-1 encoding plasmid. Full-length and excision PCR amplicons are 3020
and 532 bp, respectively. DNase or RNase enzyme pretreatments were performed prior to
treatment to control for excision attributable to unencapsulated therapeutic payloads. Nonnanoparticle controls were tested in parallel as labeled. pTatDE: TatDE CRISPR-encoding
plasmid; DE RNP: TatDE CRISPR ribonucleoprotein.
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3.4. DISCUSSION

A final hurdle in utilizing CRISPR to eliminate HIV-1 from organisms lies in its
delivery. CRISPR co-inventor, Jennifer Doudna, has reiterated this challenge as it pertains
to all therapeutic applications178. Regulatory agencies remain apprehensive about utilizing
gene therapy due to its unstudied toxicities. Recent findings elucidating the abortive
potential to embryos caused by off-target effects with CRISPR-Cas9 might justify these
concerns179,180. Additional fears stem from using viral vectors, particularly lentiviruses, to
transduce CRISPR. Lentiviruses rely on random integration of transgenes into host nuclei.
Thus, their therapeutic potential could be offset by their abilities to disrupt human genes or
induce oncogenic transformations181,182. To address these possible shortcomings as they
pertain to TatDE lentiviral therapy, we continue to develop alternative strategies of
deploying CRISPR to inactivate latent HIV-1.
One of the principal difficulties in a CRISPR approach for HIV-1 lies in the need
to inactivate all replication-competent proviral copies throughout the body. CRISPR
clinical trials for sick-cell anemia183 (NCT03745287) and spinal muscle atrophy184
(NCT02122952) provide evidence that even a partial relief of pathogenic genotypes could
alleviate disease. By contrast, complete silencing of HIV-1 with CRISPR is necessary to
terminate viral reseeding. It is estimated that only one per million proviral copies give rise
to replicating HIV-1185. Nonetheless, two strategies exist to bring therapeutic quantities of
CRISPR to each infected CD4+ leukocyte either in circulation or latent in anatomic
reservoirs. First, non-discriminant delivery oversupplies CRISPR systemically with the
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understanding that non-target cells will also receive the therapy. Concerns to this approach
include side effects and production requirements that accompany the higher dose needed
to achieve HIV-1 elimination. Administration of CRISPR via AAV9 (at 1012 gc / ~25 g
mouse) or VSVg-pseudotyped lentivirus stand as two examples. Alternatively, a targeted
approach would facilitate CD4-specific therapy. VLPs pseudotyped with HIV-1 envelope
bearing gp120 serves as one such example. Though not successful in its current form, the
appeal of utilizing a targeted vector like the HIV-1 VLP lies in its presumed lower dosage
requirement given that the therapy should primarily identify CD4+ cells as its destination.
Regardless of which modality is selected, the threshold for therapeutic effect in the case of
HIV-1 is higher than for other diseases.
Among the modes of CRISPR delivery tested, each has its merits and pitfalls. Both
AAV9 and lentiviruses have already demonstrated proof-of-concept for in vivo
elimination113,155. An advantage of AAV rests in that it is lowly immunogenic and thus
regarded as potentially safer186. The inabilities of AAV9 to transduce macrophages and
CD4+ T cells in vitro could stem from low expression of their natural ligand, sialic acid,
who glycosylation pattern likely differs in the body. However, high multiplicities of
infection are required to observe therapeutic effects1. Although lentiviruses’ transduction
efficiencies are higher than those of AAV117, the presence of neutralizing antibodies and
ART in the bloodstreams of HIV-positive patients might blunt their CRISPR therapeutic
efficacies118. Nanoparticles represent a scalable alternative to viral-based CRISPR delivery
for HIV. Despite sparse preliminary data, the possibility of CRISPR-based excision of
HIV-1 using lipid coated mesoporous nanoparticles or RNPs remains open.

86

Several future directions are likely to guide the engineering of next-generation
vehicles for HIV CRISPR therapy. Firstly, we will improve the aqueous stability of our
nanoparticles by testing different poloxamers in chemically synthesizing outer lipid shells.
Secondly, we intend to direct CRISPR containing nanoparticles to cells of interest by
covalent attachment of targeting ligands to these lipid shells. Three such peptides include
HIV-1 gp120187, anti-CD28 / CD80 Fab188, and tuftsin189 that would confer tropism to CD4,
T cells and antigen-presenting cells, and macrophages, respectively. Lastly, direct fusion
of cas9 gene to different anchorage points in gag in the VLP packaging plasmid could yield
therapeutic VLPs that do not rely on avidin-biotin tethering systems for CRISPR loading.
To minimize the number of genetic manipulations, we will utilize an integrase gene pointmutant rather than deleting large portions of RT plus integrase as we had previously
attempted. These efforts could thus boost the likelihood of delivering CRISPR to CD4+
cells while minimizing off-target toxicities.
In summary, alternatives to lentiviral-based TatDE CRISPR delivery are actively
sought. Limited rAAV9 transduction and VLP efficacy in CD4+ leukocytes highlight two
such routes with room for improvement. To this end, nanoparticles represent a
customizable and scalable platform on which to expand CRISPR therapeutic delivery for
HIV-1 elimination.
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3.5. METHODS

Protocols for cell culture, cloning and plasmid extraction, RT activity assay, and
transfection are reported previously in this dissertation.

3.5.a VLP Synthesis
HIV-1 virus-like particles (VLPs) were synthesized via Lipofectamine 3000 cotransfection of HEK293FT cells with 12.5 µg HIV-1 89.6 Env Expression Vector (pcDNA
89.6 env; NIH AIDS Reagent Program #12485) and 25 µg HIV-1 Packaging Construct
(psPAX2; NIH AIDS Reagent Program #11348), and 2.5 µg pET21a-BirA (Addgene
Plasmid #20857). For loaded VLPs, cells were preincubated with streptavidin quantum
dots (QdotTM 605 Streptavidin Conjugate; Invitrogen #Q10103MP) or biotinylated
PromoFluor-657P dye (Promocell # PK-PF647P-6-01) for 24 hours, then cells washed 3x
with PBS to remove unbound payloads, and transfected as noted above. Five days posttransfection, supernatant was centrifuged 650 x g for 10 minutes to remove cellular debris,
passed through 0.45-micron syringe filters to remove large globular proteins and exosomes,
and ultracentrifuged 112,000 x g for 3.5 hours at 4oC. Final pellets were resuspended in 0.5
mL PBS and stored -80oC. Yields were determined based of HIV-1 p24 ELISA (XpressBio
#XB-1000).

3.5.b Mesoporous Silica Nanoparticle Synthesis
Lipid film was made using 16.7mg phosphatidylcholine, 8.3mg DSPE PEG 2000, 3.3mg
cholesterol, 8.3mg dioleoyl phosphatidylethanolamine (DOPE) dissolved in 1:4
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hexanes:choloform and roto-vaped until a thin translucent film formed. Film was dried
overnight under vacuum. Silica NP (2.5mg) was mixed with 200ug plasmid (~200uL) and
diluted with PBS to 1.5mL total volume. Silica-plasmid mixture was shaken for 5 hours at
RT. Next the mixture was spun down at 6000g for 10 minutes. Supernatant was removed.
Silica-plasmid pellet was resuspended in 200uL cell culture grade PBS and then added to
the lipid film round bottom flask. The flask and contents were vortexed for minimum of 2
minutes. After 2 minutes, a further 300uL of PBS was added and the flask was vortex until
all solid lipid had de-adhered. Dummy particles followed the same protocol without
plasmid.

3.5.c TZM-bl luciferase assay
TZM-bl cells (NIH AIDS Reagent Program #8129) were cultured in 90% DMEM, 10%
fetal bovine serum (FBS), and 100 U / mL penicillin plus streptomycin (PenStep). Cells
were seeded at 250,000 cells / well in 12-well plates and incubated with HIV-1ADA (50 ng
/ mL or 2 ng / mL) or HIV-1 VLPs (2 ng / mL) for 24 hours. Thereafter, cells were washed
3x with sterile PBS, and incubated in culture medium for 7 days with media replacement
every other day. Luciferase luminescence assay was performed using manufacturer’s
protocol (Promega #E1500).

3.5.d LTR-1 / GagD Excision PCR
PCR reactions were set up using 150 ng of template DNA from pooled biological triplicates
with 12.5 µL FailSafeTM Buffer D (Lucigen #FS99060), 0.5 µL enzyme, 0.5 µL forward
primer (5’-AATTGCGGCCGCTGGAAGGGCTAATTTGGTCCC-3’), 0.5 µL forward
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primer (5’-TGTCACTTCCCCTTGGTTCTCTC-3’), and volume increased to 25 µL with
water. Nested reactions using 2 µL of 1:10 diluted PCR product were set up identically
using forward primer 5’-AAAAGAATTCGTGGATCTACCACACACAAGGC-3’and
reverse primer 5’-AAAAGGATCCACCATTTGCCCCTGGAGGTT-3’. Thermal cycling
conditions for initial PCR and nested PCR were as follows: 94oC for 5 minutes; 30 cycles
of 94oC for 30 seconds, 55oC for 30 seconds, 72oC for 30 seconds; 72oC for 7 minutes; 4oC
hold.

3.5.e Droplet Digital PCR (ddPCR) for Proviral DNA
Water–oil emulsion droplet technology was employed, using the ddPCR™ Supermix in
the QX200™ Droplet Digital™ PCR system (Bio-Rad Laboratories, Hercules, CA). For
quantification of saCas9 transcripts cDNA was synthesized from experimental culture
RNA using Verso cDNA Synthesis Kit (Thermo Scientific #AB1453A). A total of 100 ng
DNA from each experimental condition was used as template for two ddPCR
amplifications. The first PCR was performed for human beta-actin (reference gene) using
forward

primer

5’-TGGACTTCGAGCAAGAGATG-3’,

GAAGGAAGGCTGGAAGAGTG-3’,

and

reverse

primer

probe

5’-

5’-FAM-

CGGCTGCTTCCAGCTCCTCC-ZEN-IowaBlackFQ-3’. The second PCR was performed
for

HIV-1

gag

(gene

of

interest)

TCAGCCCAGAAGTAATACCCATGT-3',
CACTGTGTTTAGCATGGTGTTT-3',

using

forward

reverse
and

primer

primer
probe

5'5'-

5’-FAM-

ATTATCAGAAGGAGCCACCCCACAAGA-ZENIowaBlackFQ-3’. Data acquisition
and analysis were done using QX200 droplet reader and QuantaSoft™ software provided
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with the instrument. The genomic DNA extracted from a total of 50,000 human cells was
used as template for each ddPCR analysis.
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CHAPTER 4
Europium Sulfide Nanoprobes
Guide Design of Tissue-Penetrating HIV-1 Elimination Agents

4.1. ABSTRACT

Designing CRISPR-Cas9 and antiretroviral nanoparticles with enhanced abilities to reach
viral reservoir sites remains an important focus in achieving HIV-1 elimination. Among
the developmental bottlenecks are the requirement to serially sacrifice animals to analyze
effects in tissues. The ability of nanoformulated antiretrovirals (nanoART) to reach tissues
of interest have been extended by medicinal chemistry and formulation science, as
exemplified by long-acting slow-effective release antiretroviral therapy (LASER ART). To
establish parameters necessary for HIV-elimination agents to reach target sites, we
assessed theranostic intrinsically radiolabeled (177Lu) europium sulfide (177LuEuS)
nanoprobes as surrogates for nanoformulated rilpivirine (NRPV), a long-acting therapy for
HIV-1. Results demonstrate that both particles are rod-shaped with diameters measuring
250-350 nm. Uptake studies revealed a dynamin-dependent pathway for nanoparticle
uptake by HIV-infectible CD4+ T cells and monocyte-derived macrophages. SPECT-CT
and MRI molecular non-invasive imaging illustrate similar biodistribution patterns for EuS
and NRPV, leading to terminal accumulation of both particles in murine spleens. These
data support utilizing theranostics to identify existing limitations with nanoART and set a
foundation for CRISPR nanoparticle tracking in vivo.
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4.2. INTRODUCTION
Infection by human immunodeficiency virus type I (HIV-1) necessitates lifelong adherence
to antiretroviral therapy (ART) to suppress viral transmission and delay the onset of
acquired immunodeficiency syndrome (AIDS). Lack of continued access to treatment,
negative stigma, and drug associated toxicities all contribute to the 41% of HIV-positive
patients globally who fail oral medications190,191. In the absence of ART, HIV-1 replicates
unchecked in mononuclear phagocytes (MP; monocytes, macrophages, and dendritic cells)
and CD4+ T lymphocytes, which prompts selective cell death of the latter. Integration of
proviral DNA in long-lived MP and resting memory CD4+ T cells leaves hosts reliant on
ART to block transcription and translation of HIV-1 genes. A simplified long-acting ART
regimen is therefore desirable for pre-exposure prophylaxis (PrEP) for individuals at high
risk of acquiring the virus or in sustaining latency as part of a cure for HIV-1.
Clinical trials completed in recent years demonstrate the utility of nanoformulated
antiretrovirals (nanoART) as long-acting HIV-1 maintenance therapy. These include longacting rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI; RPV)192, and
the integrase strand transfer inhibitor cabotegravir (INSTI; CAB)193. Encasing these drugs
in polymer excipients facilitates a slow dissolution of drugs from intramuscular injection
sites. Plasma drug levels of protease inhibitors (PI) ritonavir, indindavir, atazanavir (ATV)
and the NNRTI, efavirenz, were raised 1.5-4 fold as NanoART encased in poloxamer 188
excipients. Once monthly dosing using nanoART has been demonstrated as a non-inferior
regimen to daily oral therapy192-194. Despite simplified dosing regimens, inadequate
delivery of INSTI to lymph nodes195 and sequestration of nucleoside reverse transcriptase
inhibitors (NRTIs) by adipose tissues196 prompt concern of unimpeded viral replication in
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tissues despite maintaining undetectable levels of virus in circulation. Thus, further
characterization of nanoART biodistribution is warranted.
Long-acting slow-effective release antiretrovirals (LASER ART) improve the
pharmacokinetic profiles and trafficking abilities to HIV-1 reservoir sites as compared to
nanoART. LASER ART converts standard antiretrovirals to lipophilic and hydrophobic
nanoformulated prodrugs197. Consequently, drugs more easily permeate lipid bilayers
leading to enhanced uptake, while the slow ester hydrolysis of hydrocarbon promoieties
yields back the active compound over prolonged periods. LASER ART formulations of
rilpivirine and cabotegravir exhibit prolonged apparent half-lives, maintaining plasma 90%
effective concentrations (EC90) for 6 months and 1 year, respectively198,199. LASER ART
can not only be utilized as monotherapy for PrEP200,201, but in HIV-1 elimination strategies
as well. One third of infected humanized mice were sterilized of HIV-1 when combination
LASER ART and CRISPR-Cas9 therapies were utilized155. A four drug LASER ART
cocktail administered in multiple doses proved essential to inducing viral latency prior to
the genetic excision of proviral DNA with CRISPR-Cas9. Long acting antiretroviral
injectables and their LASER ART correlates thus advance the drugs’ utility beyond means
of viral suppression.
Defining the parameters that limit nanoART’s delivery to lymphoid tissues could
aid in the design of more effective delivery schemes for LASER ART and CRISPR-Cas9
nanoparticles. Furthermore, guiding principles for antiretroviral nanoparticle formulations
are desired to accelerate the developmental pace for long-acting antiretrovirals and
CRISPR-Cas9 curative agents, whose lengthy evaluation periods already impede the rapid
identification of new efficacious candidates.
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Theranostics bridge the divide between therapeutic and diagnostic tools. Previous
iterations of HIV-1 theranostics include spherical europium cobalt-ferrite (EuCF)134 and
bismuth sulfide nanorods (BSNRs)133. These core scaffolds, doped with rilpivirine133,134 or
dolutegravir132 (an INSTI), revealed characteristics of particle release in macrophages and
the utility folic acid decoration to enhance uptake. Utilizing the inherent properties of the
metal cores or inserting radiolabel tags has further enabled real-time non-invasive tracking
of the particles’ biodistribution in animals using fluorescence, magnetic resonance imaging
(MRI), and single photon emission computed tomography (SPECT-CT). These successes
have allowed the prediction of drug biodistribution 28 days post-dosing based on early
bioimaging composite data133.
Therefore, the tracking potential of theranostics provide a platform upon which to
build nanoparticles in pursuit of HIV cure. More specifically, by assessing where nanoART
travel both intracellularly and anatomically post-administration we will obtain a model to
design against. Targeting latently infected memory CD4+ T cells in lymph nodes and tissue
macrophages with LASER ART at HIV-1 reservoir sites is thus a prerequisite to precluding
resumption of the viral lifecycle during CRISPR endonuclease function. Herein, we test
the concept that theranostics and nanoART with similar size and shape will display parallel
biodistributions. The synthesis of a novel theranostic agent, europium sulfide (EuS) is
affirmed then validated as a model for cellular uptake. EuS nanoprobes elucidate a potential
dynamin-mediated mechanism for direct nanoparticle endocytosis by CD4+ T cells, a
principal target of HIV-1. Real-time and non-invasive molecular imaging also reveal the
utility of EuS as companion particles for NRPV in trafficking nanoparticles to known
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reservoir tissues, like spleen. These advances signal how theranostic agents may serve as
surrogates to better design next-generation ART and CRISPR tools for HIV-1 cure.
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4.3. RESULTS

4.3.a Europium Sulfide (EuS) Synthesis and Chemical Characterization
Intrinsic "Chelator-free" radiolabeled europium sulfide (177Lu EuS) was first
synthesized by solvothermal precipitation of europium (III) chloride hexahydrate and 1decanethiol in the presence of oleic acid, oleylamine and octadecene with
element at 290 °C synthesis reaction shown in Figure 4.1A.

177

LuCl3 hot

The synthesized divalent

state 177LuEuS exhibited blue fluorescence, magnetic properties, the highest radiolabeling
efficacy, and optimized nanorods shape formation. Parallel reactions were performed with
without lutetitium177 chloride to enable non-radioactive experiments. Lipid coatings
containing

L-α-phosphatidylcholine

and

DSPE-PEG2000

were used

to

make

biocompatible lipid coatings for EuS particles. Transmission electron microscopy (TEM)
revealed that EuS nanocrystals had rod shapes of 25 nm in diameter by 350 nm in length
(Figure 4.1B). These approximate the 250 nm and 350 nm hydrodynamic diameters of
NRPV and a LASER ART rilpivirine prodrug, NM3RPV, previously described198. High
resolution (HR)-TEM images (Figures 3.1C-E) show the lattice fringes with spacings of
0.36-0.37 nm. High-angle annular dark-field scanning TEM (HAADF-STEM) illustrate
europium (Eu; red) and sulfur (green) as an approximate 70%:30% composition (Figure
4.1F).
The XRD shown in Figure 4.1G reveals that all peaks are indexed into a cubic crystal and
reconfirmed with the JCPDS file for Eu and S or bulk EuS (JCPDS file numbers; 01-0736349;26-1419; 05-001-0200; 04-007-2069). The XRD peaks of 14.5°, 15.0°, 17.0°, 25.0°,
27.3°, 29.35°, 31.6°, 34.7°, 40.5°, 41.85°,43.8°, 46.63° and 50.9° at 2θ are typical
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indication for face-centered cubic planes of EuS crystal structure. For example, 111, lattice
spacing approximate 3.6 Å = 0.36 nm, corresponding to 25.0° in 2θ and 0.36 nm spacing
obtained through HR-TEM (Figures 3.1C-E). The energy dispersive X-ray spectroscopy
(EDX) analysis demonstrated “europium” and “sulfur” signals were detected in the EuS
nanoprobes (Figure 4.1H). Synthesis and characterization results indicate that

177

LuEuS

nanoprobes could be employed as multi-modal theranostics agents for SPECT and MRIbased real-time visualization nanoformulated ART of similar size and shape to HIV-1
sanctuary sites.

4.3.b Multimodal trackability of EuS Nanoparticles
To ascertain the potential of EuS as surrogates for NRPV tracing in vivo, the
nanoprobes were tested for compatibility with a range of bioimaging modalities.
Fluorescence provides a sensitive means of detection across short distances. Fluorescent
blue spectra for EuS revealed maximal excitation and emission at 410 nm and 510 nm,
respectively (Figure 4.2A). Fluorescence EuS is due to electrons transition from the 4f7
ground state to 4f6 5d1 (Eu (II))vi. Similarly observed results from europium-containing
nanotubes have been attributed to a +2 oxidation state that yields blue light upon UV
wavelength excitation202. Intact NRPV likewise emits fluorescence, albeit at a shorter
wavelength (385 nm), as a result of inherent aggregation induced emission203. The MRI
compatibility of EuS was also determined as a means of quantifying particle accumulation
at different tissue depths. At issue lies the propensity of f à d transition block electrons to

vi

https://pubs.acs.org/doi/full/10.1021/jp509253e?src=recsys;https://pubs.acs.org/doi/pdf/10.1021/acs.jp
ca.9b09755?ref=vi_geerlings-festschrift
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preferentially oxidize Eu2+ to Eu3+, whose MRI relaxivity is short-lived204. The T2
weighted relaxivity constant of EuS nanoprobes measured 0.5177 ppm / second and
showed strong linear correlation with europium concentration (Figure 4.2B). High T2
weighted relaxivity paired with blue wavelength emission suggests a coordinate electron
stability conferred to europium by sulfide atoms. Finally, gamma-ray emitting lutetium177 (177Lu) was intrinsically doped into the cores of EuS nanoprobes to provide a final
means of sensitive bio-tracking via SPECT-CT. The particle stability and half-life of
177

LuEuS was experimentally found to be ~3.4 days under physiological conditions (37oC

in serum matrix), which represents a 45-50% reduction from control-incubated (6.2 days)
and native lutetium-177 (6.7 days) half-lives (Figures 3.2C-F). The radioactivity profile
of 177LuEuS indicates that the nanoprobes are compatible with SPECT-CT bioimaging over
a short duration.
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Figure 4.1

Figure 4.1. Synthesis and characterization of EuS particles.
Synthesis scheme EuS particles, solvothermal technique were used to synthesize EuS
particles in the presence of 1-dodecanethiol, oleylamine and oleic acid. 1-dodecanethiol
served as reducing agent and sulfur precursor; a vial shows fluorescent properties of
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particles. Low-resolution TEM image of EuS are illustrated in (B). The EuS dimensions
were approximately 50-80 nm in diameter by 370-500 nm in length. HR- TEM images
single EuS particle with lattice planes with 0.37 nm and correspond with XRD data (C).
The selected area electron diffraction (SAED) pattern of EuS are shown characteristic
interplanar spacing of the EuS single crystal structure (D-E). The Eu (red) and sulfur
(green) element STEM mapping showed element localization within the particles by
corresponding high-angle annular dark-field electron microscopy (F). XRD patterns (G),
correlations with HR-TEM lattice pattern and SAED data sets confirmed the particle's
structural configurations. Particles chemical composition was assessed by EDX
demonstrated the qualitative measurements of particle element distribution were made by
energy dispersive X-ray spectroscopy (H).

4.3.c Endocytic Pathways of EuS Nanoparticle Uptake
We next examined the propensity for HIV-1 infectible CD4+ T cells and monocytederived macrophages to endocytose EuS nanoparticles. A non-cytotoxic concentration of
10 ppm Eu153 was determined by mitochondrial vitality assay over 24 hours in CEMss
CD4+ T cells (Figure 4.3A). Next, a time course of EuS nanoparticle uptake in CEMss
cells revealed 52% uptake of 10 ppm Eu153 treatment (Figure 4.3B). The one-site saturation
kinetic modeling of EuS uptake indicates a delayed mechanism for nanoparticle entry that
becomes apparent between 4 and 8 hours post-treatment. To investigate a possible
mechanism for EuS nanoprobe endocytosis by CD4+ T cells, a 24-hour uptake experiment
was repeated in the presence of chemical inhibitors. Clathrin, dynamin, or actin related
protein 2/3 (Arp 2/3) complexes were blocked with Pitstop2205, Dynasore206, and
CK666207, respectively. Dynamin blockade with Dynasore elicited reductions in NRPV
(50%) and EuS (35%) uptake (Figure 4.3C-D). Notably, clathrin
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Figure 4.2

Figure 4.2. (177Lu)EuS Multimodal trackability.
Intrinsic tracking properties of europium sulfate (EuS) nanoprobes. (A) Fluorescence
spectra of resuspended EuS at λmax 410 nm excitation. (B) R2 relaxation rate (inverse T2
value) was determined using serial dilution of EuS phantom particles in agar matrix.
Integrity of 177Lu intrinsic doping in EuS nanoparticles was determined 10.2 µCi of
177
LuEuS were spiked into tubes lacking (control) or containing 400 uL of media or Balb/c
mouse plasma. Samples were then incubated at 25oC or 37oC. At various timepoints,
samples were centrifuged 77,424 x g for 30 min and supernatant removed. Gamma
emission was measured in the resulting cell pellets by dosimetry. (C, D) Stability was
calculated by normalizing radioactivity of experimental pellets against those of control. (E,
F) The half-lives of 177LuEuS were calculated using one-phase decay algorithms of
radiation levels across times using GraphPad Prism.
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Figure 4.3

Figure 4.3. Dynamin-mediated endocytosis of EuS nanoparticles by CEMss T cells.
(A) EuS cytotoxity in CEMss T cells after 24-hour incubation was determined by MTT
assay; 10 ppm treatment was used as the highest non-cytotoxic treatment concentration for
subsequent studies. (B) Time course of EuS uptake when treated at 10 ppm Eu153 was
measured by ICPMS. Saturation kinetic curve was fitted to experimental data using 1-site
saturation curve in GraphPad Prism v7.0. (C-D) The mechanism of nanoparticle uptake
was assessed by pre-treating with clathrin-inhibitor (Pitstop2), dynamin/caveolin-inhibitor
(Dynasore), and actin-mediated active transport (CK666). (E) Transmission electron
micrgrographs of CEMss T cells in the absence (left) or presence of EuS (center). Far right
micrograph (inset of center) depicts nanoparticle within endocytic pit. Bar graphs depict
mean ± standard error of the mean (SEM) of three biological replicates. Statistical
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differences were determined using two-way ANOVA between groups with a Bonferroni's
post hoc-test to correct for multiple comparisons. *p < 0.05 & ns = non-significant

inhibition by Pitstop2 also attenuated NRPV accumulation in CD4+ T cells (Figure 4.3C).
Further evidence for EuS nanoparticle uptake in these cells was observed by transmission
electron microscopy (TEM) (Figure 4.3E). The reduction of EuS uptake with dynamin
inhibition paired with the appearance of endocytic pits in the context of nanoparticle
treatment, suggests that caveolin rather than clathrin or actin line the cytoplasmic surface
of CD4+ lymphocyte cellular invaginations208.
Macrophages, which serve as long-term depots for nanoformulated LASER ART
throughout the body, were likewise assayed for EuS phagocytic uptake. MTT assessment
indicated no decline in mitochondrial vitality at concentrations up to 100 ppm Eu153
(Figure 4.4A). Monocyte-derived macrophages (MDM) displayed maximal uptake
between 2-4 hours post treatment, with 28% of the treatment phagocytosed by the cells
(Figure 4.4B). These levels approximate the 10% NRPV uptake reported in MDM
previously203. Co-treatment with Dynasore significantly reduced EuS uptake in MDM by
40% (Figure 4.4C). Pitstop2 and CK-666 markedly lowered EuS uptake by 36% and 20%,
respectively. Together, these data point to enhanced and rapid uptake of EuS by
macrophages in a caveolin-dependent manner although clathrin and actin cytoskeleton
rearrangements may also aid in phagocytosis of EuS.
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Figure 4.4

Figure 4.4. EuS uptake in monocyte-derived macrophages (MDM).
(A) EuS cytotoxity in MDM T cells after 24-hour incubation was determined by MTT
assay. (B) Time course of EuS uptake of cells treated with 100 ppm Eu153 over 24 hours
was measured by HPLC. Saturation kinetic curve was fitted to experimental data using 1site saturation curve in GraphPad Prism v7.0. (C) The mechanism of nanoparticle uptake
was assessed by pre-treating with Pitstop, Dynasore, and CK666 endocytic inhibitors.
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4.3.d Biodistribution of EuS using Real-Time Bioimaging
Intrinsically doped 177LuEuS particles were assessed for their acute biodistribution
upon reaching the blood stream. To accelerate redistribution from muscle depots formed
by long-acting antiretroviral intramuscular administration while also bypassing first-pass
metabolism, mice were dosed sequentially with NRPV (45 mg / kg) followed by 177LuEuS
(500 µCi / mouse) via tail-vein injection (Figure 4.5A). Bioimaging by SPECT-CT
revealed an initial accumulation of nanoprobes in lungs by 24 hours (Figure 4.5B-C). This
finding was unexpected but indicative that the 300-500 nm length of our particle likely
causes it to become entrapped in pulmonary capillaries during intravenous administration.
By 48 hours, 177LuEuS were readily imaged in known HIV-1 anatomic reservoirs including
spleen, liver, lungs, colon, and lymph nodes. SPECT-CT performed 5 days post-dosing
illustrated the highest accumulation of 177LuEuS in spleen.
An extended 30-day time course was used to examine EuS nanoprobe
biodistribution via MRI. T2 weighted images revealed initial accumulation of EuS in liver
two days post dosing, with significant redistribution to spleen between days 10 and 30
(Figure 4.7C). A limitation of EuS as T2 contrast nanoprobes was observed by their lack
of enhancement in hollow organs like lungs, ileum, and colon (data not shown). EuS was
also undetectable in lymph nodes and brain. These results highlight the value in designing
rod-shaped nanoparticles for trafficking payloads to the spleen, a known secondary
lymphoid organ with high levels of immunocyte interactions.
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Figure 4.5. Europiumsulfur (EuS)
nanoparticles
redistribute to spleen.
(A) Male Balb/c mice (n
= 5) were tail vein
injected with 500 uCi
with lutetium-177
intrinsically doped
europium-sulfur
(177LuEuS) nanoparticles
and imaged by SPECT
CT at various time
points. Regions of
interest were drawn
using VivoQuant v3.0
(Invicro Imaging
Software) based on
anatomy observed in
plain CT. Thereafter,
SPECT and CT data
were overlaid. (B) Mice
were serially imaged by
SPECT at various time
points over the course of
5 days. (C)
Radioactivity was
quantified in SPECT-CT
regions of interest using
VivoQuant 3.0. The
density of signal was
computed for all regions
of interest and plotted
(average ± SEM) in
GraphPad Prism v7.0.

107

4.3.e EuS Accumulation in Organs Approximates NRPV Biodistribution
Comparative analyses were performed to determine the utility of EuS nanoprobes
as predictive biotrackers for NRPV distribution. Necropsied organs collected 5 days postdosing revealed greatest accumulation of drug in spleen (202 ng / g tissue), lung (172 ng /
g tissue), lymph nodes (131 ng / g tissue), and liver (98 ng / g tissue) (Figure 4.6A). Parallel
findings were observed using gamma-ray scintillation counting, which reflects lutetitium177 content (Figure 4.6C). Europium-153 concentrations were also observed to be highest
in the spleen (212 µg / g tissue), lung (306 µg / g tissue), and liver (97 µg / g tissue) by
day 5 as measured by ICP-MS (Figure 4.6B). Lower metal contents observed in lymph
nodes at day 5, as compared to rilpivirine, could result from variability in the sizes and
locations that lymph nodes collected at the time of harvest. In contrast, the high amounts
of europium-153 and lutetium-177 in kidney likely represents their metabolic excretion
through urine versus rilpivirine whose innate hydrophobicity lends itself to deposition in
fat and solid organs.
Mass spectrometry for drug and metals performed at day 30 post-dosing revealed
similar accumulations to those found at day 5. In particular, NRPV was readily detectable
in spleen (33 ng / g tissue), liver (9.3 ng / g tissue), and lungs (5 ng / g tissue) (Figure 4.7A).
Europium-153 measured 1479 µg / g tissue in spleen, 261 µg / g tissue in liver, and 123 µg
/ g tissue in lungs (Figure 4.7B). Replicate values for NRPV and EuS in colon and brain
approached assay detection limits. The comparable accretion of both particles in
macrophage rich organs suggests phagocytic processes are vital in determining the
biodistribution of nanoformulated theranostics.
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Pearson correlations validated the significance of these trends at early and late
timepoints. Spleens from dual-treated mice sacrificed demonstrated correlation between
rilpivirine and europium-153 concentrations (p = 0.0498; Figure 4.6D). Other organs
failed to exhibit statistically significant associations between nanoprobe and drug (data not
shown). This may relate to differences in organ perfusion or overall animal health in the
context of dosing with radioactive materials. Metanalysis from terminal sacrifice also
displayed a significant correlation (p < 0.0001) between rilpivirine and europium-153
present in each organ (Figure 4.7D). As the high accumulation of both EuS and NRPV in
spleen anchored this trend, it is possible that the utility of EuS in predicting drug content
dissipates in organs that serve as minor depots for ART.
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Figure 4.6

Figure 4.6. Day-5 quantitative analysis of RPV and EuS in mouse tissues.
Male Balb/c mice (n=5) were dosed sequentially with 177LuEuS (500 µCi / mouse) and
nanoformulated rilpivirine (45 mg/kg) and assessed for biodistribution at terminal day-5
post-injection. (A) NRPV drug concentration was measured in various tissues by UPLCMS. (B) Europium-153 concentration was quantitated by ICPMS. (C) Gamma-ray
emission from necropsied tissues was measured after brief radioactive decay by
scintillation counting. (C) Raw radioactivity was divided by total radioactivity in all tissue
measured per animal, giving percent injected dose, which was further normalized against
tissue weight (% ID/g). (D) Pearson correlation between NRPV drug concentration values
and europium-153 was determined in spleen samples.
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Figure 4.7

Figure 4.7. EuS correlates with NRPV biodistribution at 30 days.
Male Balb/c mice (n= 5) were dosed sequentially with EuS (20 mg/kg) and nanoformulated
rilpivirine (45 mg/kg) and assessed for biodistribution at terminal day-30 post-injection.
(A) NRPV drug concentration was measured in various tissues by UPLC-MS. (B)
Europium-153 concentration was quantitated by ICPMS. (C) T2 maps were generated
from EuS-treated, MRI-scanned mice. ΔR2 signal was calculated as inverse T2 from preand post-treatment scans across the experimental time course. (D) Day-30 Pearson
correlation was calculated between average NRPV drug concentration and europium-153
concentration for each organ.
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4.4. DISCUSSION

Successful implementation of long-acting antiretrovirals and their prodrug correlates,
LASER ART, for HIV-1 pre-exposure prophylaxis (PrEP) and cure requires drugs’
delivery to infectible leukocytes and viral reservoir sites throughout the body. Several longacting antiretrovirals, including the non-nucleoside reverse-transcriptase inhibitor
(NNRTI) rilpivirine, have demonstrated non-inferiority as part of HIV-1 maintenance
therapy192. Given that nanoART injections are not indicated for induction therapy, and that
standard antiretrovirals confer lower levels of CRISPR mediated excision in Jurkat T cell
cultures114, we sought to characterize nanoARTs’ limited abilities to reach target sites.
Sensitive nanoprobes with bioimaging capabilities offer a surrogate means to trace
antiretroviral biodistribution while reducing the cost, labor, and time otherwise required to
survey drug concentrations at tissues of interest. Herein, we validated the utility of
europium sulfide (EuS) nanoparticles as mimetics for nanoformulated rilpivirine (NRPV)
cellular uptake and biodistribution.
Although macrophages have long been characterized for their ability to
phagocytose antiretroviral nanocrystals, antiretroviral efficacy is not solely a property of
cellular uptake. Prior works revealed that rod-shape, use of poloxamer excipients, and -to
a limited degree- surface decoration with folate, all modestly enhance nanoART uptake by
MDM209,210. Theranostics have recapitulated these findings131,132. Here we present
dynamin/caveolin as an endocytic pathway for nanoparticle entry to MDM. The key to
nanoART’s antiviral activity in MDM lies in endosomal trafficking. As revealed with
(nanoATV), atazanavir accumulates in late endosomes where HIV-1 virions are present in
high abundance211,212. By contrast, prodrug LASER ART nanoformulations are present in
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high abundance within late- and recycling endosomes213,214. We postulate that while
LASER ART and nanoART both meet their targets in endosomes, prodrugs are hydrolyzed
to

their

active

forms

under

increasingly

acidic215

endosomal

/

lysosomal

microenvironments whereas native ART become degraded. HIV-1 and LASER ART
employ recycling endosomes for sustained release from cells201. Accordingly, CRISPR
nanoparticles for HIV-1 elimination should be engineered to withstand acidification in
endosomes to enhance the potential of successfully cleaving proviral DNA.
An alternative to macrophage-mediated delivery in vivo rests in the direct uptake
of particles by CD4+ T cells. As dynamin but not clathrin blockade significantly impeded
EuS and NRPV uptake, we conclude that CD4+ T cells endocytose nanocrystals in
caveolin-coated pits which operate in tandem with dynamin “pinching” of invaginated
surfaces during endocytic vesicle formation. This finding accords with other studies that
describe dynamin-2 as critical in CD4+ T lymphocyte endocytosis of T cell receptors216
and HIV-1217. Dynamin-2 enables HIV-1 transmission between adjacent T cells217 and
triggers appropriate clonal expansion via mTOR-cMyc signal cascades when TCR
encounters cognate antigen216. As such, dynamin likely serves as an important cytoskeletal
protein involved in transmission of vesicle-bound materials within its limited cytoplasm.
Inclusion of rare earth metals, like europium, in CRISPR nanoparticles would confer the
ability to track its migration through T cells’ endosomal network via fluorescence.
Theranostics- "diagnosis and treatment" incorporated in one nanocrystal- play an
essential role in tracking therapeutic cargo in vivo.

177

LuEuS exhibit uniform rod shapes,

size, with inherent fluorescence with magnetic properties.

177

LuEuS was modified with

lipids and transferred from lipophobic to lipophilic to expand the in vivo and in vitro
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tracking applications. The simplified EuS design, which eliminates the need for transition
metals to complex with europium, conferred predictive multimodal trackability across 30
days. Unlike previous nanoprobes bearing cobalt-ferrite cores132,134, sulfur atoms
sufficiently stabilize europium (II) oxidation state. This enhanced its blue-wavelength
fluorescence and T2 weighted contrast capabilities. Sulfur is a preferred coordinate binding
partner to other inorganic elements as a result of its high biocompatibility95,218, antioxidant
capacity219, and low cost. Europium-153 concentrations correlated with rilpivirine content
in macrophage rich organs including spleen, liver, and lungs. Rilpivirine nanocrystals were
previously shown to be present in up to 15% of circulating monocyte / macrophages in
vivo203. Although rilpivirine nanocrystals exhibit inherent fluorescence, the dissolution of
these nanocrystals leads to loss of aggregation-induced emission203. Accordingly, EuS
proved useful as a surrogate for rilpivirine concentration for up to 30 days, particularly in
splenic tissues. Non-invasive SPECT-CT and magnetic resonance imaging revealed
redistribution from lung tissues to macrophage-rich regions including liver and spleen.
Alongside the development of 14-carbon ester-linked rilpivirine prodrug (“M3RPV”),
pharmacokinetic studies showed NRPV control at detectable limits in liver, spleen, lymph
node, and gut for a period of 56-days198. In light of our findings, it may be prudent to
examine whether NRPV or NM3RPV are also abundant in lung. The profusion of alveolar
macrophages in lung, Kupffer macrophages in liver, and marginal zone macrophages in
spleen likely underlie the biodistribution of EuS and NRPV. Although EuS were observed
in lower quantities within lymph nodes as compared to NRPV, EuS is still likely to be
present in splenic periarteriolar lymphoid sheath (PALS) that is rich in CD4+ T cells220.
High density lutetitium-177 signal emanating from the spleen at day 5 and T2-weighted
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contrast at day 30 may also indicate that marginal zone- and red-pulp macrophages readily
engulf EuS nanoprobes. In summary, EuS nanoprobes whose size and shape approximates
that of NRPV display similar trafficking to murine spleens.
EuS nanoprobe biotracking in vivo reveals two parameters that should be avoided
in formulating CRISPR-Cas9 nanoparticles for HIV-1 elimination. First, nanoparticles
should be made with long-axis diameters below 350 nm. This will serve to ensure that
CRISPR therapeutics do not become entrapped in pulmonary capillaries that not only blunt
systemic dissemination but could pose risk of pulmonary and cardiac failure. On balance,
nanoparticles size must exceed 24 nm to avert inducing disseminated intravascular
coagulation221. Second, lipid components present in the particle’s protective shell, core or
complexed with CRISPR ribonucleoprotein should be of sufficient hydrophobicity to
permeate lymph nodes. Analysis of rilpivirine LASER ART, NM3RPV, shows that the
hydrophobic prodrug but not nanoART NRPV control accumulate in high concentrations
within lymph nodes198. Reaching lymph nodes, where latently-infected memory CD4+ T
cells are predominantly located, is critical for CRISPR to sterilize infected hosts222.
Future investigations are planned to address several of the limitations uncovered
with EuS nanoprobes. Firstly, intramuscular injection of EuS is warranted to better
simulate the route of long-acting antiretroviral administration. Second, we will further
characterize the utility of europium-153’s fluorescence via confocal microscopy and flow
cytometry to assess EuS uptake by different cell types in vivo. Third, histological
assessments will enable us to determine the degree of EuS toxicity, if any. Finally, the
DSPE-PEG2000 lipid shell can be complexed to targeting ligands such as folic acid and
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tuftsin to evaluate whether surface modification improves particle delivery to
reticuloendothelial organs.
To conclude, EuS nanoprobes retain multimodal molecular imaging potential for
the assessment of rod-shaped nanomaterials in vivo. Advantages to this composition
include reduced requirement for transition metals in particle synthesis, which confers
improved biocompatibility to EuS and lowers production cost. Overall, these technologies
provide a platform to accelerate the pace of nanoformulated antiretroviral therapy
development, maximize delivery of therapeutics to viral anatomic reservoirs, and inform
the design of CRISPR nanoparticles for HIV-1 cure.
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4.5. METHODS

4.5.a Materials: Chemicals and Reagents.
Rilpivirine nanoformulations (NRPV) were manufactured using an Avestin EmulsiFlexC3 high-pressure homogenizer (Ottawa, ON, Canada). NRPV was prepared to best
replicate RPV LA developed by Janssen223. The preparation of RPV freebase,
manufacturing of nanoformulation of RPV (NRPV). The physiochemical methods used in
this report for particle characterization and stability, UPLC-MS/MS parameters for drug
concentration

determinations

were

performed

as

previously

(https://www.sciencedirect.com/science/article/pii/S0168365919305346).

reported.
L-α-

phosphatidylcholine,Tween-80, Europium (III) chloride hexahydrate, 1-dodecanethiol,
oleic acid, and oleylamine was obtained from Sigma-Aldrich. 177LuCl3 was obtained from
the National Isotope Development Center, Oak Ridge National Laboratory, Oak Ridge,
TN, USA. DSPE-PEG2000 was purchased form CordenPharma.

4.5.b Cells
CEMss CD4+ T cells (NIH AIDS Reagent Program #776) were cultured in RPMI 1640
containing 2 mM L-Glutamine, 10% fetal bovine serum, and 100 U / mL penicillin plus
streptomycin (PenStrep). Monocytes, obtained from human HIV-1/2 and hepatitis
seronegative donor elutriation according to a UNMC Institutional Review Board exempt
protocol, were differentiated to macrophages by culture in Dulbecco’s Modified Eagle
Media (DMEM) containing 4.5 g / L glucose, 10% pooled human serum, 1000 U/mL
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macrophage colony stimulating factor (M-CSF), 1% glutamine, 50 µg/mL gentamicin, and
10 µg/mL ciprofloxacin for 7 days. MDM experiments were performed in similar media
lacking M-CSF.

4.5.c Animals
Male Balb/cJ mice (8 weeks old) were purchased from Jackson Laboratories (Bar Harbor,
Maine, USA). Animals were housed in the University of Nebraska Medical Center
(UNMC) Comparative Medicine animal facility according to the Association for
Assessment and Accreditation of Laboratory Animal Care guidance. The UNMC
Institutional Animal Care and Use Committee approved all protocols related to animal
experiments and were certified to have met the requirements and ethical guidelines set forth
by the National Institutes of Health in handling laboratory animals for research.

4.5.d NRPV synthesis and nanoformulation
Rilpivirine nanoformulations (NRPV) were manufactured using an Avestin EmulsiFlexC3 high-pressure homogenizer (Ottawa, ON, Canada). NRPV was prepared to best
replicate RPV LA developed by Janssen223. Specifically, 1% (w/v) P338 was dispersed in
H2O, followed by the addition of 10% (w/v) RPV-free base and mixing overnight.

4.5.e Synthesis of intrinsically radiolabeled 177LuEuS particles
Intrinsically radiolabeled

177

LuEuS particles, were prepared by a solvothermal technique

in isolated radioactive workstation. Europium (III) chloride hexahydrate (0.2 mM ~72 mg),

118

3.0 mL 1-dodecanethiol, oleic acid (0.5 ml), and oleylamine (4 ml) were mixed in a glass
vial and this mixture was stirred for 30 min and followed by bath sonication to make
complete dispersion. Then, ~70 mCi of 177LuCl3 and 1-Octadecene (5 mL) were mixed
in a separate vial and transferred to the Europium-oleic acid-oleylamine (Eu-OA-OAm)
mixture. 1-dodecanethiol (3.0 mL) was quickly added reaction medium and the mixture
was sonicated for 15 minutes to completely homogenous mixtures. After vigorous stirring
for 10 min, the solution was transferred into a high safety Teflon-lined reactor that was
placed in a stainless-steel autoclave reactor, sealed airtight, and heated at 290°C for 1 hour.
The systems were then allowed to naturally cool to room temperature (around 8 hours).
After reaching room temperature, the reactor was opened in a controlled, radioisotope
workstation. 50 mL of ethanol was added followed by vortexing and sonication. The
solution was then centrifuged at 976 x g (3000 rpm) for 30 minutes at 15°C. 177LuEuS
particles were collected and purified by repeating the same ethanol washing process three
times to remove non-reacted components. Radioactivity of

177

LuEuS was measured by

gamma counter (CRC®-25R dose calibrator, Capintec, Inc, Florham Park, NJ, USA)
(activity was ~ 60mCi). Lipid coated 177LuEuS particles were prepared by the thin-film
dispersion technique. First, 100 mg L-α-phosphatidylcholine and 50 mg DSPE-PEG2000
were dissolved in a chloroform/hexane mixture (5:1 v/v) contained within a roundbottomed flask and evaporated to form a thin film using a rotavap (Heidolph, Hei-VAP
Precision; G3B Vertical, USA). The films were dried under vacuum overnight (18 hours)
to ensure to complete removal of organic solvents. Second, 177LuEuS were dispersed in
chloroform (4 mL) followed by bath sonication for 10 min to get a uniform dispersion of
the particles in the solvent. The 177LuEuS- chloroform dispersion was mixed with 3 mL of
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2% (v/v) Tween-80 in a 25 mL round-bottom flask and sonicated for 5 minutes to form a
turbid
177

metalosome

emulsion.

Third,

chloroform

was

removed

from

the

LuEuS/chloroform/Tween-80 emulsion by rotavaporation. Lastly, the 177LuEuS particle

solution was transferred to the lipid film coated round-bottomed flask and dispersed in the
lipid film through gentle rotation at 45°C with continuous bath sonication. 177LuEuS in the
was used for radioactivity analyses. Non-radiolabeled EuS particles were synthesized by
the same technique except 177LuCl3.

4.5.f Radiolabeled particle stability
The in vitro stability of 177LuEuS was determined by spiking 10.2 µCi of 177LuEuS (~100
µL) were incubated in tubes lacking or containing Balb/cJ mouse serum at 25oC or 37ºC
for 7 days. The samples were centrifuged at 77,474 x g for 30 minutes at 10ºC (Refrigerated
Centrifuge 5417R, Eppendorf North America, Hauppauge, NY, USA). The supernatant
was collected into a separate microcentrifuge tube. The radioactivity in the pellet and the
supernatant were measured by gamma counter. To determine percent stability the
following equation was used; Radiolabeling stability (%) = radioactivity in pellet/total
radioactivity (pellet plus supernatant).

4.5.g Cellular uptake of NRPV and EuS
For T cell studies, wells were precoated with 100 µg / mL poly-L-lysine for 1 hour after
which time contents were removed and washed 1x with sterile PBS. CEMss CD4+ T cells
or MDM were seed in 12-well plates at 1 x 106 cells / well in 1 mL media. NRPV was
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diluted to 10 µM T cell treatment. EuS was diluted to 10 ppm and 100 ppm for T cell and
MDM treatments, respectively. Chemical inhibitors were spiked into appropriate wells at
final concentrations of 30 µM for Pitstop2, 100 µM for Dynasore, and 4 µM CK666. At
designated time points, supernatants were discarded, cells washed 3x with 1 mL PBS, and
counted by trypan blue exclusion staining. Thereafter, collected contents were centrifuged
650 x g for 5 minutes at 4oC to pellet nanoparticle containing cells. Pellets were stored for
quantitation by of inorganic material (ICP-MS) or drug (UPLC-UV/Vis).

4.5.h SPECT and gamma scintillation of 177LuEuS biodistribution
SPECT imaging was performed on mice to assess the in vivo biodistribution of 177LuEuS.
Each animal received 500 µCi of 177LuEuS plus 45 mg / kg NRPV. Images were acquired
at 6, 12, 24, 48, and 120 hours post injection using a SPECT-CT system (Flex Triumph,
TriFoil Imaging, Northridge, CA, USA) fitted with a five pinhole (1.0 mm per pinhole)
collimator. First, CT images were acquired using 360 projections over 360° with an X-ray
tube current of 140 mA and voltage of 75 kilovoltage peak (kVp) at a magnification of 2.0
(field of view = 59.2 mm2). Immediately after, SPECT image acquisition was performed
with the following parameters; 64 projections at 15 second per projection over 360° using
a radius of rotation of 48 mm (field of view = 59 mm2). Co-registration of anatomical CT
images and functional SPECT was performed by 3D visualization and analysis software,
VivoQuant 3.5 (Invicro Boston, MA, USA). ROIs were drawn over various organs and
radioactivity content and organ volume were determined to calculate counts per cubic
millimeter (mm3). Mice were sacrificed 5 days post-injection and various organs including
heart, lungs, liver, pancreas, stomach, spleen, small intestine, large intestine, kidneys,
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bladder, lymph nodes, muscle, bone, brain, testes, injection site (tail), remaining carcass
and blood were collected, weighed, and analyzed ex-vivo for radioactivity using gamma
counter scintillation spectrometry (ORTEC NaI(Ti) Scintillation Radiation Detector,
Ametek, Oak Ridge, TN, USA). Additionally, animals were individually caged so that
excreted signal could be measured from the bedding. Signal measured was back-calculated
to the time of injection to account for radioactive decay of 177Lu (t1/2 = 6.64 days). The
signal from each tissue was normalized to the sum of total counts from all sources and then
divided by the weight of the organ to obtain % injected dose (ID) / g for each tissue.

4.5.i MRI Relaxometry Measurements
MRI data were acquired on a 7T/16 cm Bruker PharmaScan MRI system (Bruker;
Ettlingen, Germany). T2-relaxtion maps were generated using a CPMG (Carr Purcell
Meiboom Gill sequence) phase-cycled multi-echo sequence. Single slice (0.5 mm slice
thickness) data were acquired with 3000 ms repetition time, 50 echoes (echo times TEn =
n x 10 ms; n = 1), 256 x 128 acquisition matrix, 50 x 50 mm field of view (FOV), 2
averages, for a total scan time of 13 min. For T2 map measurements, CPMG phase-cycled
3-dimensional multi-echo sequence data was acquired with 250 ms repetition time, 48
echoes (echo times TEn = n X 2.618; n = 1,…,48), 128 × 128 × 64 acquisition matrix, 70
× 64.76 × 42.38 mm FOV, one average, for a total scan time of 34 min.
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4.5.j Rilpivirine quantitation by UPLC-UV/Vis
Rilpivirine concentrations from in vitro experiments were measured as described
previously198. Briefly, RPV was detected using a Waters ACQUITY ultra-performance
liquid chromatography (UPLC) H-Class system with TUV detector and Empower 3
software (Milford, MA). RPV samples were separated on a Phenomenex Kinetex 5 µm
C18 column (150 × 4.6 mm) (Torrance, CA). RPV was detected at 285 nm, using a mobile
phase consisting of 65% 50 mM KH2PO4, pH 3.2, and 35% ACN and a flow rate of 1.0
mL/min. Drug content was determined relative to peak areas from drug standards (0.05–
50 µg/mL) in MeOH.

4.5.k Rilpivirine quantitation by UPLC-MS/MS
UPLC-MS/MS drug quantitation was performed on tissues from mice dosed with
(177Lu)EuS + RPV (45 mg / kg) that were sacrificed 5 and 30 days post-treatment in
accordance with existing laboratory protocol198. Drug concentrations in tissue were
determined by UPLC-MS/MS using a Waters Acquity UPLC-Xevo TQ-S micro mass
spectrometry system (Milford, MA). RPV was separated using an AQUITY UPLC-BEH
shield RP18 column (1.7 µm, 2.1 mm × 100 mm) with a 7 min gradient mobile phase
consisting of A (7.5 mM ammonium bicarbonate in Optima-grade H2O adjusted to pH 7
using acetic acid) and B (100% Optima-grade MeOH) at a flow rate of 0.25 mL/min.
Mobile phase B remained at 70% for the initial 4.75 min, followed by an increase to 95%
B in 0.25 min and held constant for 0.75 min. Mobile phase B was reset to 70% in 0.25
min and the column equilibrated for 1.0 min before the next injection. A cone voltage of
92 volts and collision energy of 56 volts were used to detect RPV. Multiple reaction
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monitoring (MRM) transition 367.032 > 127.859 m/z was used for RPV quantification.
Internal standards (IS; indinavir (IDV) 250 ng/mL; lopinavir (LPV) 500 ng/mL) was
monitored at MRM transition 614.14 > 97.023 and 629.18 > 155.03 m/z respectively.
Tissue analysis required between 10–200 mg of tissue (spleen, lymph node, liver, gut, lung,
kidney, and brain) to be diluted with 90% MeOH and homogenized. Tissue homogenates
were mixed with MeOH containing internal standard and vortexed for 3 min, followed by
centrifugation at 17,000 g for 10 min. Supernatants were collected and mixed with Optimagrade H2O for UPLC-MS/MS analysis. Tissue standards were extracted at a final
concentration of 0.5–2500 ng/mL.

4.5.l Europium-153 quantitation by ICP-MS
Europium-151 and europium-153 concentrations in mouse plasma and tissues were
determined by ICP-MS metal at the University of Nebraska-Lincoln's Spectroscopy and
Biophysics core facility.

4.5.m Statistics
Linear regressions and statistics were calculated in GraphPad Prism v7.0 (La Jolla, CA) in
accordance with figure legends. Bar graphs depicts mean ± SEM of biological triplicates.
Statistical significance was measure by two-way ANOVA with Bonferroni corrections for
multiple comparisons.
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CHAPTER 5
Conclusions and Future Directions

At least three components are required for the development of an effective HIV-1
cure. First, a means of excising integrated proviral DNA that could otherwise lead to reinfection must be obtained. Second, a mode of delivering said therapy should be generated
and optimized. Third, a strategy of ensuring that these curative measures reach target sites
throughout the body is critical. The data presented herein lays a groundwork for
demonstrating the feasibility of eliminating HIV-1 not simply in a controlled format, but
in a complex and dynamic environment with an ever-mutating target.
To overcome the challenge of HIV-1 proviral sequence diversity, we devised the
TatDE CRISPR-Cas9 system. In silico predictions reveal that at least 62% of all known
clinical HIV-1 sequences will be cleaved using dual TatD and TatE mosaic guide RNAs.
However, entire algorithms67,224 have been developed to account for mismatch tolerances
based on nucleotide positional distance from the protospacer adjacent motif (PAM).
Therefore, this figure underestimates the true rate of cleavage likely to occur, as it only
accounts for perfect complementarity between gRNA and proviral target. Our multistrain
co-transfection screen identified an average 82% reduction in viral replication using TatDE
therapy. While an association between gRNA target conservation and efficacy was
observed, interference at a 3-exon encoding locus- TatE- demonstrated the highest level of
viral inhibition. Generation of HIV-1 point-mutants at the TatD and TatE loci revealed the
differential effect of disrupting 2, 3, or 5 loci. One caveat to the evidence collected from
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the point-mutant study is number of amino-acids disrupted. Point mutant design based on
the Inference of CRISPR Edits (ICE) algorithm guided our insertion of a single glycine
near the TatD target and deletion of 4 residues at the TatE locus. Thus, the baseline levels
of RT activity detected from HIV-1NL4-3-ΔTatE but near wildtype RT activity levels with
HIV-1NL4-3-ΔTatD infection could be due to the amount of mutagenesis rather than the locus.
Creating equivalent single glycine insertional mutants at each of the gRNA target sites
would be a more unbiased assessment of the virus’ replicative fitness.
We also demonstrated lentiviruses to be a suitable mode of delivering TatDE
CRISPR to HIV-infectible leukocytes. Transduction of TatDE CRISPR using lentiviruses
at MOI 1 produced robust evidence of excision in ACH2 T cells, as marked by ~2.5 kb
dropout of proviral DNA. More importantly, this attenuated latency reversal by 94% in
these cells. The theoretical likelihood of TatDE excision in myeloid lineage cells also exists
given that co-transfection of TatD and TatE lentiviral plasmid constructs produced PCR
excision bands and lowered propensity for stimulation in U1 cells. Full lentiviral
transduction of U1 is needed to validate these observations. Our lentiviral experiments also
provide evidence that TatDE CRISPR therapy is operative on latently infected T cells. This
suggests that lentiviruses are not only apt vectors, but also antiretroviral therapies should
be administered first to induce HIV-1 latency.
In this body of work, we introduce europium-sulfide (EuS) nanoprobes as means
of tracking the biodistribution of similarly sized nanoformulated rilpivirine (NRPV)
antiretrovirals. It was concluded that the magnetic properties of europium-153 and its
doping with gamma-ray emitting lutetium-177 conferred the ability to track the particles
using real-time bioimaging: magnetic resonance imaging (MRI) and single photon

126

emission computed tomography (SPECT). Both imaging modalities showed a
redistribution of molecules from lungs to spleen, where NRPV and europium-153 similarly
accumulated. Although the intended usage for EuS was to test whether size and shape of
nanoprobes alone could predict the biodistribution of nanoformulated ART, it also proved
informative about the operative mechanisms of endocytosis in HIV infectible leukocytes.
In particular, dynamin-caveolin pathways were found to be the predominant means for
nanoparticle uptake in CD4+ T cells and macrophages. Therefore, future nanoparticlebased strategies of delivering CRISPR might exploit dynamin-mediated uptake to enhance
delivery to CD4+ leukocytes. Theranostic studies also revealed how tracer elements such
as indium-111 or paramagnetic alternatives to europium-153 could be included in the
design of mesoporous nanoparticles that are envisioned for CRISPR delivery. By
employing similar tracking modalities, we could reasonably expect to visualize CRISPR
delivery to viral anatomic reservoir sites throughout the body.
Investigation of different CRISPR vectors revealed limitations in viral-based
strategies. In vitro testing of rAAV9/CRISPR-Cas9 failed to elicit evidence of excision in
HIV-infectible leukocytes. In macrophages, no added antiviral efficacy was observed with
CRISPR co-treatment. In CD4+ T cells, a modest reduction in proviral DNA copy number
upon CRISPR co-treatment proved to be experimental artifact in the absence of clear
excision bands. Understanding how rAAV9 could sterilize humanized mice from HIV-1
but fail to sufficiently transduce HIV-infectible leukocytes in vitro remains a point of
concern. Given that saCas9 transcripts were detected by ddPCR in transduced CD4+ T
cells, experimental error seems an unlikely conclusion. Rather, it is hypothesized that a
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disparity in sialic acid glycosylation, the putative ligand for AAV entry, exists between in
ex vivo and in vivo conditions.
Non-viral candidates for TatDE CRISPR delivery include VLPs and nanoparticles.
Considerations in VLP design included removal of reverse-transcriptase and integrase as
means to limit RNA transgene transport. Although synthesis of VLPs with this
modification revealed RT activity to be below detection limits, it also likely fatally
disrupted the architecture necessary for entering leukocytes. Two tethering mechanisms,
matrix::AviTag and capsid::maxavidin, succeeded in facilitating the intrinsic loading of
streptavidin quantum dots and biotinylated small molecules, respectively, in the cores of
HIV-1 VLPs. Correction in architecture design flaws would likely facilitate targeting of
CD4+ leukocytes when pseudotyped with HIV-1 envelope. This represents an advantage
to non-selective delivery provided by standard viral vectors. Aside from lacking a
functional prototype, HIV-1 VLPs are difficult to scale up as their transfection-based
synthesis produces sub-microgram quantities per batch. Nanoparticles represent a more
suitable platform for CRISPR delivery. Advantages include that they are produced from
commercially available reagents, allowing easy scalability. Secondly, lipid shells can be
complexed with targeting ligands in the future that would enable selective transport to
CD4+ macrophages. Preliminary data support the notion that TatDE CRISPR plasmids and
ribonucleoproteins can be loaded in lipid shell-containing nanoparticles. As proviral DNA
excision was observed in HIV-plasmid transfected cells treated with these nanoparticles,
the platform represents an improvement over AAV9 and VLPs. However, parallel controls
also call attention to the need to establish nanoparticles that remain intact in aqueous
environments if they are to protect the therapeutic cargos within. Further optimization of
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nanoparticles for TatDE CRISPR could enable both tracking and CD4-targeting
capabilities.
Future works are planned to explore the utility of TatDE CRISPR for viral
elimination in vivo. Given that TatDE CRISPR employs mosaic gRNAs designed against
an HIV-1 consensus sequence, we must first validate that the therapy inactivates multiple
viral strains. Humanized mice infected with combinations of clinical viral isolates, either
from a single clade or multiple clades, could be used to evaluate the therapeutic potential
of TatDE CRISPR against quasispecies and global clades, respectively. A second point for
future experimentation lies in expanding the library of mosaic gRNAs that meet criteria for
exonic disruption. Putative loci include overlapping regions in gag / pol, vpr / tat, and nef
/ 3’ LTR. Furthermore, additional positions close to TatE could prove beneficially
targetable by hypercompact-156 and near PAM-less225 Cas endonucleases that offer greater
flexibility in selecting target regions. Finally, it is hoped that we can assess CRISPR-Cas9
pharmacodynamic effects in real-time using bioimaging. To achieve such, a dual-reporter
strain of HIV-1 will be employed wherein one LTR-driven fluorophore indicates
productive infection while a second CMV-driven fluorophore constitutively indicates viral
latency. With this tool, fluorescence emission computed tomography (FLECT)226 can be
utilized to separately surveil induction of viral latency with ART and CRISPR-inactivation
of latent proviral DNA.
To this end, a cure for HIV-1 lies within our grasp. Building upon the incremental
discoveries that characterized viral pathogenesis, established of ART as standard of care,
and finally demonstrated CRISPR as a means of ridding the body of proviral DNA, every
contribution brought this goal ever closer. Carrying our discoveries forward will thus
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enrich not only science, but quite possibly the lives of patients to whom we dedicate our
effort.
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APPENDIX I
Key Resources Table
Reagent or Resource
293FT Human Embryonic Kidney
cells
ACH2 HIV-1 infected T cells
Cells

CEMss CD4+ T cells
Stbl3TM E. coli
StellarTM E. coli
U1 HIV-1 infected promonocytes
Agar
Ampicillin
DMEM, 4.5 g/L glucose, Lglutamine & sodium pyruvate
Fetal Bovine Serum (FBS)

Media

GeneticinTM
Kanamycin
Luria Broth Base
MEM Non-Essential Amino Acids
Solution (NEAA, 100x)
OptiMEM
PenStrep (10,000 U/mL)
RPMI 1640 Medium
Sodium Pyruvate (100 mM)
Trypsin-EDTA (0.25%)
px333

pLentiCRISPR-RFP657
Plasmids
pHIV-1NL4-3-Δnef-eGFP
pREJO.c/2864

Source

Identifier

Invitrogen

R70007

NIH AIDS
Reagent Program
NIH AIDS
Reagent Program
Invitrogen
Clontech
NIH AIDS
Reagent Program
VWR
VWR
Corning

349
776
C737303
636763
165
214010
470233552
10-013CV

Atlanta
Biologicals
Gibco
BioPioneer
Invitrogen

10131-035
C0031
12795-027

Gibco

11140-050

Gibco
Gibco
Gibco
Gibco
Gibco
Addgene
Addgene
Gift from Dr.
Beat Bornhauser
U. of Zurich,
Switzerland
Gift from Dr.
Won-Bin Young
U. of Pittsburgh
NIH AIDS
Reagent Program

31985-070
15140122
11875-093
11360-070
25200056
64073

S11150

75162

(-)
11746
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NIH AIDS
Reagent Program
NIH AIDS
Reagent Program
NIH AIDS
Reagent Program
NIH AIDS
Reagent Program
NIH AIDS
Reagent Program
NEB
NEB
Thermo
Scientific
Zymo Research
NEB
Takara
Alfa Aesar
Mirus Bio
Thermo
Scientific
Thermo
Scientific
Machery-Nagel
Machery-Nagel
Invitrogen

740956
740901
15596018

ZymoPURETM II Plasmid Maxiprep

Zymo Research

D-4203-A

Agarose

Alfa Aesar
Applied
Biosystems
Fisher Scientific
NEB

J32802-22

IDT

1055771
638317

Verso cDNA Synthesis Kit

Takara
Applied
Biosystems
AB1453A

Chloroquine Diphosphate

VWR

pTRJO.c/2851
pCH040.c/2625
pCH106.c/2633
pTHRO.c/2626
pCH058.c/2960
BsaI
BbsI
Enzymes

Transfection
Reagents

Esp3I
DNase I
T4 Ligase
In Fusion HD Enzyme
Polyethyleneimine (PEI)
TransIT-Jurkat
GeneJET Gel Extraction
GeneJET Plasmid Miniprep

Nucleic Acid
Extraction

NucleoSpin RNA Virus
NucleoSpin Tissue XS Micro kit
TRIzolTM

AmpliTaq Gold™ 360 Master Mix
PCR
&
RT-qPCR

Tris-Acetate-EDTA Solution (25x)
DNA Ladder (10 kb)
PrimeTime Gene Expression Master
Mix
Lenti-XTM qRT-PCR Titration Kit
GAPDH Endogenous Control

Chemicals,
Peptides,
&

Deoxythymidine 5'-Triiphosphate
[Methyl-3H]

Perkin Elmer

11747
11740
11743
11745
11856
R0535S
R0539S
ER0451
E1009A
M0202
STO344
43896
MIR2120
K0691
K0503

4398881
BP1330-1
N0550S

4332649
AB1453/B
102624086
NET221A
001MC

150

Recombinant
Proteins

DTT (Dithiothreitol)

Ethanol
IL-7 (human recombinant)
Isopropanol

GoldBio
Boston
Bioproducts
Decon Labs
Gibco
Fisher Scientific

KCl

Fisher Scientific

MgCl2

Fisher Scientific

EDTA

Microscint 20
NaCl (5M)
NP-40 Alternative
Oligo dt pd(T)12-18)
Paraformaldehyde
PMA (Phorbol 12-myristate 13acetate)
Polybrene

BM-150

Perkin Elmer
Promega
Sigma
Invitrogen
Sigma

2701
PHC0075
BP2632-4
BP366500
AC223211
000
6013621
V4221
9016-45-9
18418012
P6148

Sigma

P8139

Millipore

Sucrose
Trichloroacetic Acid (TCA)

Fisher Scientific
MP Biomedicals

TNFa (human recombinant)

Gibco

Tris-HCl

DTT10

Boston
Bioproducts

TR-1003G
BP220-1
190521
PHC3015
L
BM-320
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APPENDIX II
Cloning Primers

Forward Oligo (5'→3')a
Reverse Oligo (5'→3')b
caccCAGAACTACACACCAGGG aaacGGCCCTGGTGTGTA
CC
GTTCTG
GagD
caccGATAGATGTAAAAGACAC aaacTGGTGTCTTTTACAT
CA
CTATC
DLTR-1 caccGACTGCTTAAGCCTCAAT aaacTTATTGAGGCTTAA
AA
GCAGTC
DLTR-2 caccGCTTTATTGAGGCTTAAG aaacCTGCTTAAGCCTCA
CAG
ATAAAGC
TatA2 caccTAGATCCTAACCTAGAGC aaacGGGCTCTAGGTTAG
CC
GATCTA
TatD
caccTCTCCTATGGCAGGAAGA aaacCTTCTTCCTGCCATA
AG
GGAGA
px333
TatE
caccGAAGGAATCGAAGAAGA aaacCCTTCTTCTTCGATT
AGG
CCTTC
TatE2
caccGAAAGAATCGAAGAAGG aaacCCTCCTTCTTCGATT
AGG
CTTTC
TatF
caccCCGATTCCTTCGGGCCTG aaacGACAGGCCCGAAGG
TC
AATCGG
TatG
caccTCTCCGCTTCTTCCTGCCA aaacATGGCAGGAAGAAG
T
CGGAGA
TatH
caccGCTTAGGCATCTCCTATG aaacGCCATAGGAGATGC
GC
CTAAGC
TatI
caccCCGATTCCTTCGGGCCTG aaacGACAGGCCCGAAGG
TC
AATCGG
Control caccGGAGACGTTTGTACGTCT aaacAGAGACGTACAAAC
CT
GTCTCC
pLenti
TatD
caccGTCTCCTATGGCAGGAAG aaacCTTCTTCCTGCCATA
CRISPRAAG
GGAGAC
RFP657
TatE
caccGGAAGGAATCGAAGAAG aaacCCTTCTTCTTCGATT
AAGG
CCTTCC
ΔTatD GAAGCGGGGGAGACAGCGAC TGTCTCCCCCGCTTCTTC
GAAGAGCTC
CTGCCATAG
pHIV-1NL4ΔTatE TAGAAGAAAGAGACAGAGAC TGTCTCTTTCTTCTATTC
3-Δnef-eGFP
AGATCCATTCG
CTTCGGGCC
a
Overhang sequences complementary to digested vector represented as lower case “cacc”
Vector

b

gRNA
LTR-1

Overhang sequences complementary to digested vector represented as lower case “aaac”
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APPENDIX III
PCR Primers

Forward Oligo
PCR

TatDE
Excisio
n

Template DNA
(locus)
HIV-1HXB2
(5518-5537)
HIV1CH040.c/2625
(5514-5533)
HIV1CH106.c/2633
(5515-5534)
HIV-1TRJO.c/2851
(5542-5561)
HIV1CH058.c/2960
(5535-5554)

Primer Name

Reverse Oligo
Sequence (5'→3')

Template DNA
(locus)

Primer Name

Primer 300

AAGCCACCTTTGCCT
AGTGT

HIV-1HXB2
(8560-8580)
HIV1CH040.c/2625
(8525-8545)
HIV-1THRO.c/2626 Primer 301
(8643-8663)
HIV-1REJO.c/2864
(8576-8596)
HIV-1TRJO.c/2851
(8586-8606)

HIV-1THRO.c/2626
Primer 302
(5549-5568)

AAGCCGCCTTTGCCT
AGTGT

HIV1CH058.c/2960
(8546-8566)

Primer 303

Sequence (5'→3')

CCAGAAGTTCCACA
ATCCTCG

CCAGAAGTTCCACA
GTCCTCG
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HIV-1REJO.c/2864
(5538-5557)

Primer 304

HIV-1HXB2
(5557-5578)
HIV1CH040.c/2625
(5553-5574)
HIV1CH106.c/2633
TatDE
(5554-5575)
Excisio
HIV-1THRO.c/2626 Primer 300b
n
(5588-5609)
(nested)
HIV-1REJO.c/2864
(5577-5598)
HIV-1TRJO.c/2851
(5581-5602)
HIV1CH058.c/2960
(5574-5595)
TatD
OffTarget

chr11:
6802230768022329

Primer 182D2 Off F

AAGCCACCTTTGCCT
AGTAT

HIV1CH106.c/2633
(8580-8600)

AGATGGAACAAGCC
CCAGAAGA

HIV-1HXB2
(8526-8552)
HIV1CH040.c/2625
(8491-8517)
HIV1CH106.c/2633
(8546-8572)
HIV-1THRO.c/2626 Primer 301b
(8609-8635)
HIV-1REJO.c/2864
(8542-8568)
HIV-1TRJO.c/2851
(8552-8578)
HIV1CH058.c/2960
(8512-8538)

CAAGAGTAAGTCTC
TCAAGCGGTGGTA

TGAACTCCAAGGGT
TCTAAGAT

chr11:
6802273368022751

TTGGAGAAGGCGTA
CAGG

Primer 305

Primer 183D2 Off R

CCAGAAGTTCCACT
ATCCTCG
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TatE
OffTarget

chr13:
9377107493771102

Primer 194D3 Off F

GTGCCAAACATATT
GATAACACATACAC

chr2:
216741039216741061

Primer 274D7 Off F

chr2:
GTTTATAATTGCAGA
216741522AGCACTG
216741539

Primer 275-

chr12:
130325120130325144

Primer 184D9 Off F

AAAGTGGATGACAA
GTTCTATCAG

chr12:
130325598130325620

Primer 185-

chr9:
8324084083240862

Primer 247D10 Off F

TCAAGGTTCTAAGTT
TCTGGCA

chr9:
8324131483241340

chr18:
3596487235964889

Primer 282E3 Off F

chr19:
4799124247991260

Primer 278E4 Off F
Primer 226-

chr4:
184272401184272421

E7 Off F

chr13:
9377155193771574

Primer 195D3 Off R

D7 Off R

CTCCTCAAAGCTCA
CCAAATTCC
AACCCAATTCTGTC
CGA

D9 Off R

AGACTTGAGATGAG
AGAAACCC

Primer 248D10 Off R

CCAGAACATAAGCT
GTAATGTAAACC

chr18:
TTCAGATGCTGGAGT
35965355AG
35965372

Primer 283-

TTAGCTGGACTTGA
TGG

GACCCAAACCAGCA
GGAG

chr19:
4799172147991742

Primer 279-

CACACAGAGGCTTT
GGAACT

chr4:
184272881184272901

Primer 227-

E3 Off R

E4 Off R

E7 Off R

GGAGGAGGTGAAG
AAGGAAGA
ACTATGTACCCAGG
CAGCTA
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LTR-1
OffTarget

chr8:
3645325936453280

Primer 244E12 Off F

GTACCTTAGAGGTTT
CCAATC

chr8:
3645373936453759

Primer 245E12 Off R

TGAAGAATCAAATG
CAACAC

chr7:
124503052124503072

Primer 373E14 Off F

CCACAGTTTATATAT
TCCAC

chr7:
124503057124503075

Primer 374E14 Off R

CTTGAAGCCACCTT
ATAC

chr1:
3697172736971747

Primer 254LTR1 Off F

AAGACTTCTAGGTG
GATAGC

chr1:
3697218936972207

Primer 255LTR1 Off R

CCTGTGGATTCTCCT
TCA

chr7:
122425478122425495

Primer 256LTR2 Off F

GTGGTCCCAAGCTA
CTC

chr7:
122425924122425943

Primer 257LTR2 Off R

GAGTTAAAGCAAGG
GTCAG

chr3:
117193688117193710

Primer 258LTR3 Off F

GTATTGCTTTAGACT
CCTAAGT

chr3:
117194162117194179

Primer 259LTR3 Off R

CAAGATCTCGGCTC
ACT

chr13:
9425105594251072

Primer 260LTR4 Off F

CCCAAATGCCCATC
AAT

chr13:
9425152694251545

Primer 261LTR4 Off R

CACAAGTTCTGGGA
TTTGG

chr19:
4778649947786517

Primer 262LTR11 Off F

chr19:
TTACAGGCATATGTC
47786908ACC
47786928

Primer 263LTR11 Off R

CTTGCTTAAACAAA
GAACTG
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chr2:
9161468991614709

Primer
264- Gag1
Off F

chr19:
3683240436832427

Primer
367Gag12 Off
F

GagD chr9:
Off- 20223152Target 20223174

Primer
369Gag13 Off
F

chr5:
112567658112567678

Primer
270- Gag4
Off F

chr3:
6233037162330388

Primer
272Gag11 Off
F

GGCATCACATCTGGGTTCAA

chr2:
9161520091615221

Primer
265- Gag1
Off R

CTTTCTGCTTCTGGCCCTATC

AGAATAGTAGTGATGCTGAACA

chr19:
3683240936832427

Primer
368Gag12 Off
R

CCAGGGCTGCTATCATTT

AGCAGCATTAAACTTGGAAAGG

chr9:
2022315220223175

Primer
370Gag13 Off
R

AGTGTTGAGATTAGAGGTGTGAG

TGCTAGGGCAGAGAGGATAA

chr5:
112568112112568134

Primer
271- Gag4
Off R

GACGTTCTCATGGAATCTCACA

ATATGGCCTGTGACCAA

chr3:
6233076262330783

Primer
272Gag11 Off
R

GCTCAGTAAGATACCTCAGTA
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